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Parkinson’s disease (PD) and cancer are two important but obviously 
disparate human disorders. However, emerging evidences suggest that the 
pathogenic pathways of the two diseases may be related.  Indeed, several of 
the PD-linked genes identified to date are also associated with cancer. Among 
these is parkin, whose mutations are a predominant cause of inherited 
parkinsonism and are currently also recognized to contribute to cancer 
development. To date, much of the interest in characterizing the function of 
the parkin gene has been directed towards understanding its role in 
neurodegeneration. Comparatively, the role of parkin in cancer is less well 
characterized. Clearly, unraveling the link between PD and cancer holds 
promise to open new avenues to novel therapeutic approaches for both groups 
of disorders.  
In the first part of this thesis, I have examined the potential role of 
parkin in breast cancer and found that parkin expression is dramatically 
reduced in several breast cancer-derived cell lines as well as in primary breast 
cancer tissues. Importantly, I was able to demostrate that ectopic parkin 
expression in parkin-deficient breast cancer cells mitigated their proliferation 
rate both in vitro and in vivo, and reduced the capacity of these cells to 
migrate. Cell cycle analysis revealed the arrestment of a significant percentage 
of parkin-expressing breast cancer cells at the G1-phase. However, I did not 
observe significant changes in the levels of the G1-associated cyclin D1 and E. 
Instead, the level of cyclin-dependent kinase 6 (CDK6) was dramatically and 
selectively elevated in parkin-expressing breast cancer cells, the extent of 
which correlated well with the expression of parkin. Interestingly, a recent 
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study demonstrated that CDK6 restrained the proliferation of breast cancer 
cells. Taken together, my results support a negative role for parkin in 
tumorigenesis and provide a potential mechanism by which parkin exerts its 
suppressing effects on breast cancer cell proliferation. 
In the second part of this thesis, I have described the isolation and 
characterization of a novel interactor of parkin known as BCA3/AKIP1 - a 
breast cancer-associaited protein. Despite its clear interaction with parkin, 
BCA3/AKIP1 turned out to be neither a classical substrate nor regulator of 
parkin. Instead, parkin promotes the stability and nucleus localization of 
BCA3/AKIP1 in a totally catalytically-independent manner. To the best of my 
knowledge, this is the first description that parkin can influence the stability 
and cellular localization of an interacting partner in a manner that is 
independent of its enzymatic activity. Moreover, under normal conditions, 
BCA3 expression does not appear to compromise parkin ubiquitination 
activity. However, under conditions when mitochondria become depolarized, 
BCA3 retards parkin-mediated removal of damaged mitochondria. Thus, the 
relationship between parkin and BCA3/AKIP1 is much more complex than I 
have originally envisaged, although I remain optimistic that my findings will 
expand the current paradigm of parkin function. 
In essence, the above findings gathered during my Ph.D candidature 
have provided important insights into the role of parkin that are relevant to 
both neurodegeneration and cancer. 





“The division of human biology into different disciplines is perhaps important 
for clarity of thoughts and focus. However, the hazard of becoming too 
focused on one’s favored discipline is the invariable progressive blindness 
towards others. The body then becomes the brain, the heart, the eyes or 
whatever the investigator’s mind is preoccupied with. The essence of life, as 
we know it, is thence lost.” 
 
The above sentiments as articulated by my supervisor aptly illustrate the need 
to remind ourselves that the human body functions as an entity. Indeed, multi-
cellular organisms like humans evolved as a result of interactions and 
interdependence amongst different cell types. Curiously, the genomic 
blueprint that gives rise to the diverse cell types in our body is absolutely 
identical. Yet, cellular morphologies amongst different subtypes can be so 
vastly different. Take for example, a terminally differentiated neuron and a 
breast epithelial cell. Intuitively, one would immediately consider them 
separately based on their distinct shape, function and site of origin. However, 
there are more commonalities between their physiology than are apparently 
recognized. By the same token, the mechanisms underlying brain and breast 
diseases may be more related than meets the eye. In the following pages of my 
thesis, I shall discuss a potential link between these two seemingly disparate 
disorders: Parkinson’s disease and breast cancer, and show that the same 
culprit, parkin dysfunction, could underlie their pathogenesis. 
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1.1  Parkinson’s Disease  
 Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder after Alzheimer’s disease. It is a debilitating 
disease that is relentless in its progression and crosses geographical, racial and 
social boundaries, affecting 1-3% of the elderly population worldwide. Despite 
intensive research and attempts made to understand its cause, the precise 
mechanism underlying PD pathogenesis remains elusive and the majority of 
PD cases are idiopathic in nature. With little known about the disease 
mechanisms, the current available treatment options could only afford 
symptomatic relief. Major drawbacks with current therapies are the inevitable 
loss of effectiveness and increasing drug-induced side effects, particularly in 
the aged population as the disease progresses. Invariably, the debilitating 
nature and morbidity of the disease presents significant social, emotional and 
economic stresses. In addition, with the majority of industrialized countries 
being made up of a rapidly aging population, the socio-economic and clinical 
impact of neurodegenerative disorders look set to rise globally. Notably, a 
recent study by Dorsey et al projected that the number of PD cases in the 
world’s ten most populous countries would increase from the current 4.3 
million to 9 million in year 2030 (Dorsey et al 2007). This is definitely a 
worrying trend. In the United States alone, the estimated annual societal costs 
related to PD amounts to $20 billion per annum. Back home, the situation is 
not any better. The prevalence of PD in Singapore was found to be comparable 
to that of the Western countries, with the incidence rate at 32 per 100,000 
people over the age of 50 (Tan et al 2007). As our country’s population ages 
rapidly, with the elderly set to occupy about 20 percent of the total population 
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by 2030, we will not be spared from the problems associated with PD. There is 
therefore an urgent need for better understanding of the underlying causes of 
the disease in order to develop more effective treatment modalities for the PD 
patient. 
 
1.2  Clinical and Pathological Hallmarks of Parkinson’s Disease 
 From the time when James Parkinson first provided a detailed 
description of the symptomatic manifestations of PD in his essay on the 
“shaking palsy” in 1817, we have come a long way in our understanding of the 
disease. Remarkably, the present diagnosis of PD still hinges on the detection 
of physical telltale signs and symptoms originally described by James 
Parkinson that includes resting tremor, cogwheel rigidity, postural instability 
and bradykinesia (difficulty in initiating movements). However a modern-day 
neurologist would also be aware of the pathological changes that underlie 
these clinical manifestations as well as the very broad spectrum of non-motor 
symptoms that accompany the motor features associated with PD (Olanow & 
Tatton 1999). The principal neuropathology that gives rise to the constellation 
of motoric deficits seen in PD patients is unequivocally the loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the 
midbrain, which results in the severe depletion of striatal dopamine (DA). 
Aside from this, additional neuronal cell death could also be seen in other 
brain regions such as the locus coerulus, dorsal motor nucleus of the vagus and 
olfactory regions that are associated with non-motoric clinical symptoms 
exhibited by PD patients (Braak & Braak 2000). 
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 Another pathological hallmark that has been traditionally associated 
with PD is the presence of intracytoplasmic proteinaceous inclusions known as 
Lewy bodies (LB). The LB is usually found within the soma of neurons and 
has a core that is enriched in ubiquitin and α-synuclein (a PD-linked 
presynaptic protein). Additional proteins identified by mass spectrometry, 
such as those involved in protein misfolding, membrane trafficking, oxidative 
stress and interestingly, several kinases (MAPKK1/MEK1, protein kinase C) 
and ubiquitin ligases have also been found to reside within the LB 
(Wakabayashi et al 2007).  
 
1.3  Molecular Pathogenesis of PD 
Although the etiology of PD remains incompletely understood, a broad 
range of studies conducted over the past few decades, including 
epidemiological, genetics and post-mortem analysis, as well as in vitro and in 
vivo modeling, have provided tremendous insights into the pathogenesis of 
PD. In particular, the functional characterization of recently-identified PD-
linked genes, including α-synuclein, parkin, DJ-1, PINK1 and LRRK2 (Gupta 
et al 2008; Thomas & Beal 2007), has contributed significantly to our 
understanding of disease development and progression. Here, I shall briefly 
discuss two popular hypotheses that have emerged from these studies. 
 
1.3.1 Dysfunction in Protein Clearance Machinery 
The presence of protein aggregates within LBs in over 90% of patients 
diagnosed with PD would immediately suggest the involvement of aberrant 
protein homeostasis in disease pathogenesis. Notably, two intracellular protein 
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degradation systems are essential for the maintenance of protein homeostasis, 
i.e. Ubiquitin-proteasome system and the autophagy system. Defects occurring 
in either or both of these systems may contribute to PD pathogenesis. 
Ubiquitn Proteasome System and PD - The UPS is a major cellular 
degradation system crucial in maintaining cellular homeostasis through the 
removal of unwanted or damaged proteins. Proteins that are destined for 
degradation by the UPS, are covalently tagged with ubiquitin, a 76 amino acid 
residue protein, through a series of enzymatic reactions whereby the terminal 
residue (G76) of one ubiquitin is linked to a lysine residue (K48 usually) of a 
previous ubiquitin via the sequential actions of the ubiquitin-activating (E1), -
conjugating (E2) and ligating enzymes (Pickart 2001) (Fig. 1.1). This ligation 
process is usually repeated several times to form a polyubiquitin chain, which 
then targets the substrate for degradation by the 26S proteasome, a large 
cylindrical protease complex, made up of a barrel-shaped 20S proteolytic core 
and capped at both ends by the 19S (P700) regulatory subunits. The two 
regulatory 19S caps contain multiple ubiquitin binding sites which are vital to 
the recognition, unfolding and transfer of polyubiquitinated substrates into the 
lumen of the proteolytic core. Ubiquitin monomers are then regenerated by 
deubiquitinating enzymes (DUBs), while the ATPase active sites on the 
regulatory caps are responsible for the hydrolysis of ATP molecules in this 
energy-driven process (Fig. 1.1). It is important to mention that ubiquitination 
is not restricted to targeting proteins for degradation. Involvement of 
ubiquitination in other cellular functions such as signaling and protein 
trafficking have also been demonstrated (Hicke & Dunn 2003; Mukhopadhyay 
& Riezman 2007). These processes often involve mono-, multi-mono or 
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polyubiquitin chains that are formed using one of the other six lysine residues 
at amino acid positions 6, 11, 27, 29, 33 and 63 of ubiquitin (Peng et al 2003). 
Notably, both monoubiquitination and K63-linked ubiquitination are thought 
to participate in cellular processes that are not typically associated with 
proteasomal degradation (Tan et al 2008a).  
 
Fig. 1.1 Ubiquitin-proteasome and PD. Under normal circumstances, proteins 
marked for proteasomal degradation are tagged with a polyubiquitin chain after 
repeated rounds of a sequential reaction involving ubiquitin-activating (E1), -
conjugating (E2) and –ligating (E3) enzymes. Ubiquitin hydrolases (DUBs), on the 
other hand catalyzes the removal of ubiqutins thus ensuring constant renewal of 
monomeric Ub pool. Energy in the form of ATP is used to drive the UPS machinery. 
Parkin is a multifunctional E3 ligase which catalyzes K48-polyUb, as well as K63-
polyUb and mono-Ub. Both mono-Ub and K63-polyUb are usually not associated 
with proteasome degradation. Exogenous and age-related stresses, mitochondrial 
dysfunction and mutations in PD-linked genes are thought to be contributory factors 
that promote UPS dysfunction, resulting in the accumulation of protein aggregates 
that are harmful to the cell survival. (Reproduced from Lim KL, 2007, Expert Review 
in Proteomics, 4, 769-781) 
 
Given that the UPS represents the major protein degradation machinery 
in the cells and that ubiquitin-enriched LB is a key hallmark of PD brains, one 
Introduction    16 
would intuitively suggest that functional impairment of the UPS may be a root 
cause of PD. Supporting this, levels of oxidized proteins (which are normally 
removed by the UPS) in the brains of PD patients are elevated compared to 
normal controls (Alam et al 1997). Further, the chymotrypsin-like, trypsin-like 
and peptidyl glutamylpeptide hydrolytic activities of the 20S proteasome are 
found to be significantly reduced in extracts prepared from SN but not in other 
regions of the sporadic PD brains compared to normal controls (McNaught & 
Jenner 2001). Corroborating these findings, another study demonstrated a 55% 
reduction in the chymotrypsin-like activity of the proteasome in SN, but not 
frontal, cingulate or occipital cortex of PD brains (Tofaris et al 2003), 
although one other study showed that proteasomal activity in several regions 
of the brain, including striatum, was not reduced but increased in PD brains 
compared to controls (Furukawa et al 2002). Finally, the discovery of two PD-
linked genes: parkin and UCHL-1 encoding for components of the UPS 
provides direct evidence for a role of the protein degradation system in PD 
pathogenesis. Parkin functions as a ubiquitin ligase (see later sections), while 
UCHL-1 is a de-ubiquitinating enzyme. Importantly, disease-associated 
mutations in these two enzymes have been demonstrated to compromise their 
activities (Lim 2007). Together, these findings suggest that optimal UPS 
function is required for neuronal homeostasis. Further supporting this, the 
accumulation of α-synuclein, a major component of LBs (Spillantini et al 
1997), is known to inhibit proteasome function. In its native form, wild-type 
α-synuclein is usually unfolded and demonstrates great folding flexibility 
which ironically also predisposes the protein to greater chances of misfolding 
and aggregation (Uversky et al 2001). Importantly, multiplication of wild-type 
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α-synuclein gene as well as missense mutations, have been shown to increase 
their propensity to aggregate and inhibit proteasome function, as determined 
by in vitro 20S proteaseome assay (Chen et al 2006; Stefanis et al 2001; 
Tanaka et al 2001). Apart from the genetic evidences presented, various 
exogenous neurotoxicants related to PD, including pesticides, herbicides and 
metal ions, have been shown to hasten α-synuclein aggregation (Betarbet et al 
2000; McCormack et al 2002; Sherer et al 2002), thus providing a link 
between gene and the environment in disease pathogenesis. Taken together, 
UPS dysfunction leading to neurodegeneration is likely a result of two 
independent but connected events: the aberrant functions of proteins critical to 
the maintenance of protein homeostasis and the accumulation of proteins that 
disrupt the protein clearance machinery, invariably leading to 
neurodegeneration. 
 
Autophagy Dysfunction and PD – Emerging evidence suggests that 
derangements in the autophagy-lysosomal pathway (ALP) may also be linked 
to neurodegeneration (Hara et al 2006; Komatsu et al 2006; Wong & Cuervo 
2010). There are three types of ALP: macroautophagy, chaperone-mediated 
autophagy (CMA) and microautophagy. All three pathways conclude with the 
delivery of intracellular components to the lysosomes where lysosomal 
hydrolases within an acidic environment, proceed to break down their 
vesicular contents into metabolic building blocks which are then recycled and 
reused by the cell. The ALP differs in many ways from the UPS in that it 
functions to degrade long-lived proteins and most notably, it carries out 
degradation of cellular organelles via macroautophagy.  
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 Autophagy first begins with the formation of isolation double-
membrane structures which are both cup- or rod-shaped and this step is termed 
‘initiation’. These structures then undergo a series of processes that include 
nucleation, cargo recognition and expansion, to eventually form the 
autophagosome (AP). Several genes, known as autophagy-related genes 
(Atgs), are involved in the orchestration of these steps and have been well-
characterized (Klionsky 2005). In neurons, AP can be found at distal axonal 
sites, located far away from perinuclear lysosomes (Hollenbeck 1993). This 
therefore highlights the importance and dependency of autophagy on cellular 
transport machinery i.e. microtubule network, in the redirection of AP from 
such remote locations to the perinuclear region. Accordingly, ubiquitinated 
misfolded proteins are transported along microtubules to the microtubule 
organizing center (MTOC) by their association with HDAC6 (a microtubule-
associated deacetylase) and the dynein motors, to form large perinuclear 
structures known as aggresomes (Johnston et al 2002; Kawaguchi et al 2003; 
Kopito 2000). Autophagy is one of the major pathways by which large 
structures like aggresomes and organelles such as mitochondria (mitophagy) 
and peroxisomes (pexophagy) are cleared (Garcia-Mata et al 2002). Unlike 
normal cells, post-mitotic neurons are extremely reliant on constitutive 
autophagy in the maintenance of neuronal homeostasis as its genetic 
inactivation (Atg5 or Atg7) selectively in neurons, demonstrated by two 
landmark studies, leads to the formation of ubiquitinated inclusions and 
neuronal demise in mutant mice (Hara et al 2006; Komatsu et al 2006). Of 
particular relevance to PD, removal of the long-lived protein α-synuclein and 
cellular organelles such as mitochondria, are primarily dependent on the 
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autophagic machinery (Chu et al 2007; Vogiatzi et al 2008). Notably, 
mitochondrial dysfunction coupled with the failure of selective autophagy in 
removing damaged mitochondria, apart from α-synuclein accumulations, are 
now thought to be culprits in the development of PD (Dauer & Przedborski 
2003; Hattingen et al 2009; Vila et al 2008). Neuropathological evidence in 
support of autophagy dysfunction in PD has actually been reported several 
years before the recent genetic studies. Ultra-structural examination of 
pathological specimens revealed abnormal accumulation of AP in the SNpc of 
post-mortem PD brains and the appearance of vesicular-like LBs within the 
stellate ganglion of PD patients (Anglade et al 1997; Forno & Norville 1976; 
Zhu et al 2003).  
 
1.3.2 Oxidative Stress and Mitochondrial Dysfunction 
The presence of oxidatively damaged lipids (peroxidation) and proteins 
(carbonylation) in postmortem PD brains support a role for oxidative stress in 
PD pathogenesis (Alam et al 1997). It is a well-known fact that the 
environment of the brain is prone to oxidative stress due to the high levels of 
polyunsaturated fatty acids, its high oxygen consumption (20% of the resting 
total body oxygen) and the elevated content of iron in specific regions such as 
the globus pallidus and SN (Kidd 2000). The SN is particularly pro-oxidative 
since metabolism of dopamine (DA) by dopaminergic neurons produces 
various reactive oxygen species (ROS), including peroxide, superoxide and 
hydroxyl radicals, which if not handled properly could generate considerable 
damage to the neurons. In addition, DA is chemically unstable and often gets 
oxidized to DA-quinone and superoxide anions which can further generate 
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additional ROS. DA metabolites such as 3,4-Dihydroxyphenylacetic acid 
(DOPAC) can also undergo oxidation to generate ROS and DOPAC quinones. 
These oxidative species and DA have been demonstrated to covalently modify 
macromolecules, in particular, α-synuclein and parkin (Asanuma et al 2003; 
Hattoria et al 2009; Shamoto-Nagai et al 2007). Modification of α-synuclein 
by cytosolic DA forms adducts that stabilize α-synuclein protofibrils - pore-
like structures - capable of permeabilizing membranes and vesicles, resulting 
in DA-induced cell injuries (Conway et al 2001; Volles et al 2001).                                                       
Given the high energy demands of neurons, it is apparent that the 
bioenergetic status of mitochondria in these post-mitotic cells needs to be kept 
optimal at all times and that their dysfunction would precipitate 
neurodegeneration. Perhaps due to the uniquely stressful environment of DA 
neurons, higher mitochondrial DNA mutation rate is observed in SNpc than 
any other part of the brain (Soong et al 1992). Since neurons are post-mitotic, 
any DNA damages acquired will accumulate over their lifetime leading to 
progressive mitochondrial dysfunction that eventually leads to cell death. In 
addition, there is an observed selective reduction in the activity of 
mitochondrial complex I, an important component of the mitochondrial 
electron transport chain, in the SN and frontal cortex of PD patients (Albers & 
Beal 2000; Schapira et al 1989; Zhang et al 1999). Related to this, the 
discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahhydropyridine (MPTP) being the 
cause of acute and irreversible parkinsonian syndrome in a group of drug 
abusers, more than 3 decades ago, prompted scientists to examine the 
mitochondria in greater detail (Langston et al 1983). The active metabolite of 
MPTP, MPP+, is a substrate of the DA transporter (Devi et al) and is therefore 
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selectively taken up by dopaminergic neurons whereby it accumulates and 
confers its toxicity on the latter through complex I inhibition. MPP+ mediates 
many deleterious effects, including increased ROS production and decreased 
ATP synthesis which leads to increased excitotoxicity and nitric oxide related 
cell injuries. DA release is also enhanced by MPP+ which furthers the 
oxidative damage incurred. This therefore provides a crucial link between 
idiopathic PD and mitochondrial dysfunction. 
  Given the damaging effects that ensued after mitochondria injury, the 
next most critical step for cells in their bid for survival, is to mediate clearance 
of these damaged mitochondria. As mentioned previously, autophagy is often 
the primary pathway involved in the selective clearance of mitochondria and 
this process is specifically referred to as “mitophagy”. If the mitochondrial 
damage is not too extensive and only a fraction of the mitochondrial 
population is injured, mitophagy could rescue the cell and prevent activation 
of death programs. Recent data provide evidence for the participation of PD-
associated gene products PINK1 and parkin in mediating mitophagy and 
disease-associated mutants of PINK1 or parkin were not able to mediate 
mitophagy upon mitochondrial insult suggesting that accumulation of 
damaged mitochondria could contribute to the development of PD (Geisler et 
al 2010a; Geisler et al 2010b; Narendra et al 2008; Sriram et al 2005). 
Although it remains unclear why dopaminergic neurons in the SNpc are 
preferentially lost in PD, the above evidences seem to be in support of 
oxidative stress, mitochondrial dysfunction and defective mitophagy as being 
central to the selective demise of the latter in PD. 
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1.4  PD-linked Genes 
As mentioned earlier, a subset of PD cases is inheritable and 
attributable to mutations in specific genes (Table 1.1). Whereas α-synuclein 
and LRRK2 mutations are causative of dominant parkinsonism, mutations in 
parkin, DJ-1, PINK1 are associated with recessive parkinsonism (Thomas and 
Beal, 2007).  
 
Locus Chromosome Gene Inheritance Function 
     
PARK1 & 4 4q21-23 α-synuclein (SNCA) Dominant Unclear (presynaptic protein) 
PARK2 6q25.2-27 Parkin (PRKN) Recessive Ubiquitin ligase 
PARK3 2p13 Unknown Dominant - 
PARK5 4p14 UCHL1 Dominant Ubiquitin hydrolase 
PARK6 1p35-36 PINK1 Recessive Putative serine/threonine kinase 
PARK7 1p36 DJ-1 Recessive Redox sensor 
PARK8 12p11.2-q13.1 LRRK2/dardarin Dominant Putative serine/threonine kinase 
PARK9 1p36 ATP13A2 Recessive Lysosomal P-type ATPase 
PARK10 1p32 Unknown Unknown - 
PARK11 2q37.1 Unknown Dominant - 
PARK12 Xq21-q25 Unknown Unknown - 
PARK13 2p12 Omi/HtrA2 Dominant Mitochondrial serine protease 
PARK14 22q13.1 PLA2G6 Recessive Phosopholipase 
PARK15 22q12-q13 FBXO7 Recessive Component of SCF E3 complex 
PARK16 1q32 Unknown Unknown - 
     
 
Table 1.1: PD-linked genes. (Reproduced from Tay et al., 2011, InTech book 
chapter) 
 
Interestingly, it turned out that these seemingly functionally disparate 
PD-linked proteins that have no clear relationship with each other at first 
glance may all influence either protein or mitochondrial homeostasis, with 
some, like parkin, being directly involved in both. Accordingly, in the absence 
of functional parkin, aberrations in both protein and mitochondrial quality 
control would ensue that may eventually trigger the demise of susceptible 
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neurons. Indeed, the pivotal role parkin plays in maintaining DA neuronal 
survival is underscored by our current recognition that parkin dysfunction 
represents not only a predominant cause of familial parkinsonism but also a 
formal risk factor for the more common, sporadic form of PD. 
 
1.5  Parkin and PD 
Mutations in the parkin gene are commonly associated with autosomal 
recessive form of PD that is characterized by early onset progression. 
Although the symptoms are essentially similar to PD, a major histological 
difference is the absence of LBs in most (Mori et al 1998; Takahashi et al 
1994) though not all affected individuals (Farrer et al 2001). The discovery of 
parkin which is mapped to the PARK2 locus came about in 1998 when Kitada 
et al, noticed a microsatellite marker deletion in a PD patient which 
corresponds to a five exon deletion in a gene which they later named as parkin 
(Kitada et al 1998). The typical age of onset ranges from around 20 to 40 years 
although cases before 10 years of age to over 60 years have been reported. 
Subsequent cloning and characterization identify parkin as a RING-type E3 
ligase associated with protein turnover by coordinating the transfer of 
ubiquitin to substrates thereby targeting them for degradation by the 26S 
proteasome. The participation of parkin in the UPS strengthens the hypothesis 
that protein clearance and aggregation are central to the pathogenesis of PD. 
Parkin mutations have been identified in population of all ethnic origins and 
make up 18-49% of early onset PD, making it one of the most commonly 
known genetic causes. This is in stark contrast to the restricted occurrence of 
α-synuclein and DJ-1 mutations.  
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  Although exonic rearragements, deletions and duplications are 
common, point mutations (missense, nonsense, frameshift) in the parkin gene 
are the most frequent genetic lesions, with at least 50 identified to date (Fig 
1.2). This heterogeneity may be responsible for the wide age of disease onset 
that ranges from juvenile (<10) to over 60 years of age. Despite the 
heterogeneity, there is generally no discernible difference clinically among PD 
patients with different parkin mutations, suggesting that substitutions of amino 
acids resulting from missense mutations are equally detrimental to parkin 
function as truncation and deletion mutants (Lohmann et al 2003). Initially, 
parkin mutations were thought to abrogate its E3 ligase catalytic activity. 
Although this is true for selected parkin mutations such as T415N, several 
studies later showed that many disease-associated parkin mutants retain 
significant catalytic competency (Chung et al 2001; Gu et al 2003; Imai et al 
2001; Matsuda et al 2006; Sriram et al 2005). Besides overt catalytic 
impairment, parkin dysfunction could apparently also arise from its solubility 
alterations brought about by its mutations, as demonstrated by our lab and 
others (Cookson et al 2003; Gu et al 2003; Wang et al 2005b). Accordingly, 
these mutants are found predominantly in the detergent-insoluble fraction, thus 
correlating with their tendency to form intracytoplasmic inclusions that are 
aggresome-like.  
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Fig 1.2 Parkin structure and mutations. Schematic depiction of the modular 
architecture of the parkin protein (top panel) and its corresponding exon structure 
(bottom panel). Various disease-associated parkin mutations are indicated. 
(Reproduced from Tay et al., 2011, InTech book chapter) 
 
Interestingly, normal parkin in the brain also becomes progressively 
more detergent-insoluble with aging (Pawlyk et al 2003). As age represents an 
unequivocal risk factor for PD, the depletion of soluble parkin with age is 
unlikely to be a trivial association and may reflect the progressive 
modification of parkin by cellular stress. Consistent with this, we and others 
have found that a wide variety of PD-linked stressors, including those that 
produce oxidative and nitrosative stress, induce parkin’ solubility alterations 
and thereby its aggregation in a manner analogous to that brought about by 
several of its missense mutations (LaVoie et al 2005; Wang et al 2005a; 
Winklhofer et al 2003)  
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1.6  Parkin Gene Organization and Expression 
 The parkin gene spans more than 1.43Mb and consists of 12 exons that 
code for a 465 amino acid protein. Despite the relatively small protein encoded 
by the gene, exons of parkin are interspersed by long-spanning intronic 
regions, making it the third largest human gene after dystrophin and titin. 
Presently, the role of the large introns which constitute 99.9% of the parkin 
gene is still unknown. Interestingly, the parkin promoter is extremely short – 
only 204 bp (Asakawa et al 2001; West et al 2003). Although there is limited 
knowledge of the elements that are involved in the transcriptional regulation of 
parkin, several studies have shown that they could reside in the gene as 
evident by upregulation of parkin mRNA under certain conditions, such as 
cellular unfolded protein stress (Imai et al 2000) or in the presence of agents 
such as chronic and acute administration of haloperidol, a dopamine-D2 
receptor antagonist (Nakahara et al 2001) and a neurotoxic dose of 
methamphetamine (Nakahara et al 2003). In addition, N-myc, a transcription 
factor involved in neuronal development (Bernard et al 1992), has been shown 
to negatively modulate parkin expression by binding to the E-box motif within 
the parkin promoter (West et al 2004). This is corroborated by the observation 
that several neuroblastoma cell lines with elevated N-myc expression have low 
levels of parkin protein (West et al 2004). 
Parkin is ubiquitously expressed in most systemic organs such as the 
heart, kidney, intestines, skeletal muscle and testis (Kitada et al 1998), 
suggesting that its function is not confined to the brain. Moreover, parkin 
expression in the brain is widespread and not limited to regions affected by 
PD. Other than the substantia nigra, parkin expression is also found in the 
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thalamic, cerebellar, hippocampal and cortical regions (Kitada et al 1998; 
Shimura et al 1999). In neurons, parkin expression can be seen in the cell body 
as well as processes but is not detectable in glial cells. Ultrastructurally, parkin 
is usually localized to the cytosol, membranes of organelles such as Golgi 
apparatus, ER and mitochondria, and in post-synaptic densities (D'Agata et al 
2000; D'Agata et al 2002; Shimura et al 1999). Parkin also seems to associate 
with actin filaments indicating a role in trafficking (Huynh et al 2000). 
Generally, the nucleus is devoid of parkin, although there are studies which 
suggest the possible translocation of parkin to the nucleus during DNA 
damage to participate in DNA repair (Kao 2009a; b) or transcriptional 
regulation (da Costa et al 2009). 
 
1.7  Structure of Parkin  
 The 465 amino acid long parkin is made up of a N-terminus ubiquitin-
like (UBL) domain, a C-terminus RING box domain terminating in a PDZ-
binding motif and a central unique region that links the two domains (Fig. 
1.2). The RING box of parkin is consisted of three domains that include two 
RING finger motifs (RING1 and RING2) which are separated by a Cys-rich 
in-between RING (IBR) domain. The RING box is crucial for parkin 
enzymatic activity as a ubiquitin ligase (Imai et al 2000; Shimura et al 2000; 
Zhang et al 2000). Notably, many PD-linked mutations are located in the 
RING box region, suggesting that parkin catalytic dysfunction is a major 
contributing factor in the development of recessive parkinsonism. 
 The UBL domain shares 30% identity and 62% similarity to ubiquitin 
(Kitada et al 1998). It has been shown to bind Rpn10, a proteasomal subunit of 
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the 26S proteasome, thereby facilitating the targeting of polyubiquitinated 
substrates to the proteasome (Sakata et al 2003). Related to this, a recent study 
demonstrates that the UBL domain is capable of activating the 26S proteasome 
as a result of its interaction with the 19S subunits (i.e. Rpn1, Rpn10, Rpt5 and 
Rpt6) and the promotion of greater binding affinity between these subunits 
(Um et al 2010). Besides being able to bind components of the proteasome, the 
UBL domain has also been found in a very recent study to regulate parkin 
activity by inhibiting its autoubiquitination (Chaugule et al 2011). At the 
extreme C-terminal end of parkin, a class II PDZ-binding motif bearing the 
amino acid sequence FDV, is responsible for its interaction with CASK, the 
mammalian homolog of Caenorhabditis elegans Lin-2. Interestingly, parkin 
was found not to ubiquitinate CASK via the interaction. Rather, parkin is 
targeted to the lipid rafts and postsynaptic complex in the brain as a result of 
binding to CASK, suggesting that the interaction functions to regulate parkin 
activity in subcellular compartments (Fallon et al 2002).  
 
1.8  Parkin and Protein Homeostasis 
 The role of parkin as a E3 ubiquitin ligase which governs intracellular 
protein turnover suggests that protein mishandling is a key mechanism in the 
development of parkin-related PD. Consistent with this notion, several 
pathological mutants of parkin have been shown to disrupt its catalytic activity 
directly (Shimura et al 2000; Zhang et al 2000) or by augmenting its 
aggregation thereby making it unavailable to bind and therefore, ubiquitinate 
its substrates (Sriram et al 2005; Wang et al 2005b). As a result, one would 
naturally surmise that loss of parkin function could lead to build-up of one or 
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several of its substrates, thus leading to neurodegeneration. Inevitably, this 
speculation fuelled the intense effort by many laboratories around the world to 
identify potential substrate(s) of parkin in the hope of finding the link between 
dysfunctional parkin and PD pathogenesis. Presently, at least 25 putative 
substrates of parkin have been reported since the discovery of CDCrel1 as the 
first putative substrate of parkin (Zhang et al 2000). However, none of the 
substrates identified thus far is exclusively expressed in DA neurons thus not 
accounting for the selective vulnerability of DA neurons in familial 
parkinsonism cases related to parkin mutations and deficient parkin function. 
In addition, only a few of these substrates fulfill the important criterion that 
defines an ‘authentic’ parkin substrate i.e. accumulation in the brains of ARPD 
patients and parkin-deficient models (Table 1.2). However, one should also 
reassess the long-held view that substrates of a ubiquitin ligase must display 
an accelerated, proteasome-dependent turnover in the presence of the enzyme. 
This is of particular relevance to parkin, which our laboratory and others have 
shown to be a multifaceted enzyme, capable not only of K48-linked 
polyubiquitination (proteasomal-dependent) but also of mediating alternative 
ubiquitin topologies not typically associated with proteasomal degradation 
(proteasomal-independent), such as monoubiquitination and K63-linked 
polyubiquitination (Doss-Pepe et al 2005; Lim et al 2005; Matsuda et al 2006) 
(Fig. 1.3). By virtue of its apparent dissociation from the proteasome, our 
laboratory has originally proposed that parkin-mediated K63-linked 
ubiquitination may be involved in cargo diversion during proteasomal stress to 
the juxtanuclear region where aggresomes are formed from the diverted cargo 
and subsequently cleared by autophagy (Lim et al., 2006). Thus, the lack of 
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accumulation of an identified parkin substrate under the aforementioned 
criterion does not necessarily mean that it is not an ‘authentic’ substrate. With 
this in mind, I shall now proceed to discuss selected parkin substrates that are 




Ub Type  Elevated in  Reference 
  KO mice ARJP Brain PD brain  
CDCrel-1 - Yes/No Yes/No - (Ko et al 2005) 
CDCrel-2a - - Yes - (Choi et al 2003) 
Synaptotagmin XI - Yes/No - - (Periquet et al 2005) 
Synphilin-1 K63 No No  (Chung et al., 2001; Ko et al., 
2005; Lim et al., 2005) 
P38/AIMP2 Multiple 
Mono 
Yes Yes Yes (Corti et al 2003; Hampe et al 
2006; Ko et al 2005; Periquet et 
al 2005) 
FBP1 - Yes Yes Yes (Ko et al 2006) 
PARIS (ZNF746) K48 Yes Yes Yes (Shin et al 2011) 
Cyclin E - No Yes/No Yes (Ko et al 2005; Staropoli et al 
2003) 
PDCP2-1 - - Yes Yes (Fukae et al 2009) 
Pael-R - No Yes/No - (Ko et al 2005) 
α/β tubulin - Yes/No No - (Ko et al 2005; Ren et al 2003) 
Hsp70 Multiple 
Mono 
No No Yes (Moore et al 2008) 
PICK1 Mono No - - (Joch et al 2007) 
VDAC1 K27, 
Mono 
Yes - - (Geisler et al 2010a; Narendra et 
al ; Periquet et al 2005) 
Ataxin-2 - Yes - - (Huynh et al 2007) 
O-glycosylated  
α-synuclein 
- - Yes - (Shimura et al 2001) 
RanB2 - - - - (Um et al 2006) 
LIM Kinase - - - - (Lim et al 2007) 
Eps15 Mono - - - (Fallon et al 2006) 
DJ-1 L166P K63 - - - (Olzmann et al 2007) 
Bcl-2 Mono - - - (Chen et al 2010) 
Drp1 K48 - - - (Wang et al 2011) 




- - - - (Jiang et al 2004) 
Phospholipase Cγ1 - Yes - - (Dehvari et al 2009) 
Ataxin3 polyQ79 - - - - (Tsai et al 2003) 
      
 
Table 1.2: List of parkin substrates/putative substrates. (Reproduced from Tay et 
al., 2011, InTech book chapter) 
 
Synphilin-1 - Synphilin-1 is an interactor of α-synuclein and is capable of 
forming LB-like inclusions when co-expressed with α-synuclein (Engelender 
et al 1999). Synphilin-1 is a synaptic vesicle-enriched protein which has been 
found to co-localize with LBs in sporadic PD brains (Wakabayashi et al 2000). 
Subsequently, parkin was found to mediate ubiquitination of synphilin-1 and it 
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was further shown that co-expression of parkin, α-synuclein and synphilin-1 
led to formation of ubiquitin-positive inclusions (Chung et al 2001). 
Collectively, these suggest a molecular association between LB formation, the 
UPS, parkin, synphilin-1. Interestingly, parkin preferentially carries out the 
non-classical, proteasomal-independent ubiquitination of synphilin-1, 
involving lysine 63 (K63)-linked polyubiquitin chain formation which does 
not affect its turnover rate (Lim et al 2005). This has direct implication for the 
formation of LB involving α-synuclein, synphilin-1 and parkin.  
 
Cyclin E - Cyclins are binding partners of the cyclin-dependent kinases 
(CDKs) and together, they function as an active complex to regulate cell cycle 
progression. Cyclin E, together with Cdk2, regulates cell cycle process at the 
G1/S-phase boundary. The discovery of cyclin E, an interactor of hSel10, as a 
parkin substrate is in line with the role of parkin in a multiprotein ubiquitin 
ligase complex consisting of parkin, hSel10 and Cullin-1 (Staropoli et al 
2003). Aberrant cell-cycle re-entry in postmitotic neurons has been shown to 
trigger apoptosis and unsurprisingly, increased level of cyclin E is found to 
induce neuronal apoptosis (Copani et al 2001). In addition, cyclin E is shown 
to accumulate in substantia nigra extracts from parkin-deficient human PD 
brains (Staropoli et al 2003) suggesting its involvement in PD pathogenesis. 
These results suggest that accumulation of cyclin E as a result of parkin 
dysfunction could trigger cell cycle re-entry resulting in apoptosis of post-
mitotic neurons. At the same time, it also suggests the interesting possibility 
that parkin may also have roles in cancers (discussed in later sections). 
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PARIS/ZNF746 - PARIS (parkin-interacting substrate) is one of the newest 
kids on the block to join the laundry list of parkin substrates (Table 1.2). 
Parkin was found to modulate PARIS protein levels by carrying out K48-
linked polyubiquination of PARIS thus promoting its degradation by the UPS 
(Shin et al 2011). Interestingly, PARIS functions as a modulator of the 
transcriptional co-activator, PGC-1α (peroxisome proliferators-activated 
receptor gamma-coactivator 1-alpha) by binding to its promoter and repressing 
its expression. Because PGC-1α transcriptionally co-activates genes necessary 
for mitochondrial biogenesis, degradation of PARIS by parkin enables proper 
functioning of PGC-1α in mediating gene expression and mitochondrial 
biogenesis. Conceivably, when parkin function is lost, PARIS would 
accumulate thus causing suppression of mitochondrial biogenesis by PGC-1α. 
This finding elegantly linked up the connection between protein homeostasis 
and mitochondrial homeostasis and provides insights into how dysregulation 
in one system could have detrimental impact on another.  
 
1.9  Parkin and Mitochondrial Homeostasis 
One of the first hints that parkin may play a role in mitochondrial 
homeostasis aside from its role as a regulator of protein turnover came from a 
study in fruit flies. Greene and colleagues analyzed adult Drosophila parkin 
null mutant and observed that the most prominent pathology is not in the brain 
but in the flight musculature of these mutant flies, which is plagued by muscle 
degeneration and pronounced mitochondrial lesions (Greene et al 2003). 
Interestingly, PINK1 null flies were subsequently found to phenocopy their 
parkin-deficient counterparts and importantly, parkin overexpression in 
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PINK1-/- flies was able to rescue all the mutant phenotypes tested, although 
the reverse, did not happen (Clark et al 2006; Park et al 2006), suggesting that 
parkin acts in the same pathway but downstream of PINK1. We now know 
from several follow-up studies in flies and other model systems that the 
parkin/PINK1 pathway is a key regulator of mitochondrial dynamics, although 
it is currently controversial whether the pathway promotes mitochondrial 
fission or fusion.  
 In an exciting development, Narendra and colleagues from Youle 
laboratory have recently demonstrated that parkin played an essential role in 
removing damaged mitochondria from the cell via a specialized form of 
autophagy known as mitophagy (Narendra et al 2008). This has fuelled 
widespread interest amongst many researchers directed at elucidating the 
mechanism underlying parkin-mediated mitophagy, which is reminiscent of 
the initial excitement shared by many to uncover novel parkin substrates. A 
model (Fig. 1.3) that has emerged from a flurry of follow-up studies proposed 
that a key initial event that occurs upon mitochondrial depolarization is the 
selective accumulation of PINK1 in the outer membrane of the damaged 
organelle (presumably after its segregation by fission). Notably, PINK1 
accumulation in healthy mitochondria is prevented by a proteolytic event that 
rapidly cleaves the protein (Narendra et al 2010; Vives-Bauza & Przedborski 
2010). Upon recruitment to depolarized mitochondria by PINK1, parkin then 
becomes activated (Matsuda et al 2010) and promotes the ubiquitination and 
subsequent p97 AAA-ATPase-regulated degradation of mitofusins (Poole et al 
2010; Ziviani et al 2010), the elimination of which will prevent unintended 
fusion events involving damaged mitochondria and thereby their re-entry into 
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undamaged mitochondrial network from occurring (Tanaka et al 2010). The 
event is then followed by the induction of mitophagy, which is also parkin-
dependent. Parkin-mediated K63 ubiquitination is apparently important here, 
as mitochondrial substrates that are modified by K63 polyubiquitin can 
presumably help in the recruitment of autophagy receptors such as HDAC6 
and p62 to the damaged organelle. Notably, both HDAC6 and p62 are 
ubiquitin-binding proteins that preferentially recognize K63 ubiquitin chains 
(Lim & Lim 2011; Olzmann et al 2007; Tan et al 2008a). The end result is the 
formation of “mito-aggresomes” and their subsequent clearance by lysosomes. 




Figure 1.3. Role of parkin in protein and mitochondrial QC. (Left) Parkin is a 
unique E3 enzyme capable of mediating various types of ubiquitin modification on its 
substrates that would result in different outcomes. A model of parkin/PINK1-
mediated mitophagy. (Reproduced from Tay et al., 2011, InTech book chapter) 
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1.10 Parkin is a Key Neuroprotectant 
Given the critical role of parkin in regulating protein and mitochondrial 
homeostasis, it is perhaps unsurprising to note that parkin is capable of 
protecting neurons against a wide variety of insults, including those mediated 
by α-synuclein or mutant LRRK2, as well as those generated by dopamine 
quinones, neurotoxins or metallic ions (Feany & Pallanck 2003; Winklhofer 
2007). Moreover, several studies have also demonstrated that parkin can 
afford protection against neurotoxicity elicited by agents that are not directly 
related to PD. For example, parkin is apparently capable of mitigating 
cytotoxicity induced by α-amyloid or by expanded polyglutamine-containing 
proteins through facilitating their elimination from the cell (Rosen et al 2010; 
Tsai et al 2003). While the removal of aberrant proteins or damaged 
mitochondria from cells undergoing various forms of stress may be common 
denominators underlying the broad neuroprotective capacity of parkin, recent 
studies also implicated a more direct role for parkin in neuroprotective 
signalling. Indeed, parkin-mediated ubiquitination is important for the 
activation of major cellular pro-survival pathways such as the NF-κB pathway 
(Henn et al 2007). Henn and colleagues demonstrated in cells treated with 
kainate (an excitotoxin) or rotenone (a mitochondrial complex I inhibitor) that 
parkin-mediated protection against cell death is dependent on NF-κB activity 
(Henn et al 2007). Interestingly, the authors further showed that the activation 
of NF-κB pathway by parkin is associated with its K63 polyubiquitination 
activity (Henn et al 2007). Notably, several studies have also reported the 
ability of parkin to suppress stress-related mitogen-activated protein kinase 
(MAPK) signalling (e.g. JNK and p38) (Cha et al 2005; Ren et al 2009), 
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although the effect may be an indirect consequence of reduced oxidative stress 
level in the presence of parkin. 
Besides its catalytic role, parkin can also promote neuroprotection in 
an ubiquitination-independent manner. For example, Ren and colleagues have 
demonstrated that parkin does not require its ligase activity to stabilize 
microtubules and that this activity-independent function of parkin is important 
in the protection of DA neurons against microtubule-deploymerizing toxins 
(Ren et al 2009). In a separate development, a provocative report suggested 
that parkin possesses ubiquitination-independent transcriptional activity, 
which in this case acts as a repressor of the tumor suppressor p53 expression. 
The repression of p53 expression by parkin ultimately leads to decreased Bax 
transcription, caspase 3 activity and apoptosis (da Costa et al 2009). Although 
the subject of parkin’s nuclear residency is currently still controversial, it is 
noteworthy that parkin localization to the nucleus has been independently 
observed by at least one other group (Kao 2009a). Kao showed that parkin 
translocates to the nucleus following DNA damage (Kao 2009a), apparently to 
assist in DNA repair (Kao 2009b). Since parkin lacks a defined nucleus 
localization signal, precisely how the translocation of parkin occurs under 
different conditions remains to be elucidated. Notwithstanding the gaps in our 
current knowledge regarding the mechanisms underlying parkin-mediated 
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1.11 Regulators of Parkin Function 
  The recent isolation of several parkin regulators has shed light on 
ways in which parkin is modulated, and how aberrant regulation could 
impinge on parkin function. Parkin has been found to associate with numerous 
chaperones which are capable of modulating its activity. Hsp70 and CHIP are 
two such chaperones which are found to affect ubiquitination of Pael-R by 
parkin. Whereas Hsp70 association with Pael-R leads to inhibition of parkin 
E3 ligase activity, CHIP positively regulates parkin ubiquitination of Pael-R 
by promoting the dissociation of Hsp70 from parkin and Pael-R (Imai et al 
2002). Another protein that was found to negatively regulate parkin function is 
bcl-2 associated anthanogene 5 (BAG5). BAG5 belongs to the evolutionary 
conserved BAG family of proteins. These proteins are distinguished by a 
common conserved region known as the ‘BAG’ domain. This domain allows 
them to interact with and regulate Hsp70. BAG5 was found to interact with 
and negatively regulate chaperone activity of Hsp70. Further, BAG5 is 
capable of inhibiting parkin ubiquitination activity via its interaction and this 
could not be rescued in the presence of Hsp70, potentially leading to neuronal 
death. Supporting this, adenovirus-mediated expression of BAG5 in the SNpc 
of rats resulted in marked degeneration of DA neurons (Kalia et al 2004). 
Nrdp1/FLRF (RING Finger Ubiquitin-Protein Isopeptide Ligase) is another 
parkin interactor that was isolated from a yeast two-hybrid screen with parkin 
as bait. Interestingly, Nrdp1/FLRF co-expression promotes the degradation of 
parkin and thereby affecting its catalytic function (Zhong et al 2005). It is 
noteworthy to mention, that not all interaction with regulators are associated 
with modulation of the E3 ligase activity of parkin. One such example is the 
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interaction of CASK/LIN-2 with the PDZ-binding motif of parkin. 
CASK/LIN-2 does not affect parkin activity per se but rather results in its re-
localization from the cytosol to the synaptic membranes, suggesting possible 
ubiquitination of substrates found within this subcellular compartments by 
parkin. CASK/LIN-2 therefore regulates parkin activity by defining its site of 
action. Finally, besides interactor-mediated regulation of parkin, other 
modifiers such as phosphorylation (Avraham et al 2007; Rubio de la Torre et 
al 2009), S-nitrosylation (Chung et al 2004; Yao et al 2004) and DA (LaVoie 
et al 2005) have also been demonstrated to alter parkin catalytic activity  
 
1.12 Other Roles of Parkin 
 Interestingly, parkin appears to be involved in several human disorders 
other than PD. Apart from its extensive characterized role in 
neurodegeneration, parkin was recently shown to be involved in transient focal 
cerebral ischemia where ischemia-induced depletion of parkin levels leads to 
UPS dysfunction and increased sensitivity of the neurons to endoplasmic 
dysfunction during reperfusion, thus resulting in neuronal cell injury 
(Mengesdorf et al 2002). In addition, susceptibility to leprosy is found to be 
associated with parkin by comparative genomic sequencing and positional 
cloning of genetic variants from two populations with very different ethnic 
backgrounds (Vietnamese and Brazilian) (Mira et al 2004). Thesetwo studies 
suitably demonstrate the less characterized role of parkin in diseases other than 
PD. Importantly; parkin dysfunction is also implicated in cancers recently. 
Although a role for parkin in cancers may still come as a surprise to many, 
several other PD-linked genes have also been implicated in cancers. Indeed, 
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DJ-1 was originally described as an oncogene before its recent association 
with PD. Therefore an interesting relationship between PD and cancers seems 
to exist. 
 
1.13 Parkinson’s Disease and Cancer 
There is a curious notion that PD provides some form of protection 
against selected cancer types although the scientific rationale to explain this 
observation is lacking. In fact, as early as 1954, Doshay noticed that for 
reasons as yet uncertain, cancer is rare in “paralysis agitans” (classical term for 
PD) (Doshay 1954). Over the past few decades, several epidemiological 
studies have been carried out on different cohorts of PD patients and based on 
some of these well-designed surveys, there is substantial evidence for reduced 
cancer rates among patients with PD (Jansson and Jankovic, 1985, Moller et 
al., 1995, Minami et al., 2000). In two of the largest population-based cohort 
studies to date, each involving more than 10,000 PD patients (Olsen et al 
2005; Vanacore et al 1999), the overall cancer mortality risk was found to be 
reduced in individuals with PD (Fig 1.4). Notably, the observed reduction in 
cancer risk among PD patients cannot be ascribed to the well-documented low 
life-incidence of smoking in PD patients (Hernan et al 2001; Morens et al 
1995) as the risk reduction is seen not only for smoking-related cancers but 
also for non-smoking related cancers (Fig.1.4) (Vanacore et al 1999). The 
negative interaction observed between PD and cancer begs the simplistic 
hypothesis, as proposed by West et al, that a specific genetic background that 
can protect from cancer can also predispose an individual to 
neurodegeneration in PD and vice versa (West et al 2005).  
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Fig 1.4 Risks for smoking related and non-smoking related cancers in different 
genders. Relative risks for cancers at all sites combined and for individual sites in 
men and women with Parkinson’s disease in Denmark, 1977-98. (Olsen et al 2005) 
 
Despite all the evidences in support of the epidemiologically-derived 
PD versus cancer paradigm, they however, do not account for the increased 
prevalence of selected cancer types, including breast and skin cancers as seen 
in the two large population studies mentioned above. Additionally, these 
increased incidences could not be attributed to the therapeutic drugs used on 
PD patients (Elbaz et al 2005; Olsen et al 2007). At least for these selected 
cancer types that are over-represented in PD population, the same event(s) that 
lead to neurodegeneration in PD may enhance survival in dividing cells 
leading to cancer. 
 
1.14 Common Mechanisms Underlying PD and Cancer 
As discussed earlier, aberrant protein homeostasis, mitochondrial 
dysfunction and oxidative stress are thought to be pathogenic triggers of 
neurodegeneration in PD. Similar, these events are also intimately associated 
with cancer, which I shall discuss briefly here.  
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Altered protein homeostasis - Like PD, cancer can also be driven by 
protein misfolding and aggregation. For example, the tumor suppressor p53 is 
known to aggregate in tumor cells, particularly when its DNA binding domain 
is destabilized by mutations (Gannon et al 1990). Aggregated p53 can bind 
and sequester the wild-type protein and related members such as p63 and p73, 
which prevent them from triggering apoptosis (Xu et al 2011). As hypoxia is a 
characteristic of cells within the tumor mass, the ROS build up in this case 
could also promote the misfolding of pro-apoptotic and pro-autophagic 
proteins. The end result is necrosis, which promotes the release of pro-
oncogenic factors into the milieu that favors tumorigenesis of neighboring 
cells. 
Mitochondrial dysfunction - Alterations in energy metabolism is one 
of the hallmarks of cancer progression. While normal cells carry out 
mitochondrial respiration to generate energy, most cells undergoing neoplastic 
transformation preferentially perform aerobic glycolysis even in the presence 
of oxygen, a change known as the Warburg effect (Hanahan & Weinberg 
2011; Warburg 1956). Warburg attributed this shift to mitochondrial 
dysfunction in cancer cells. Precisely how abnormalities in  mitochondrial 
function triggers oncogenesis is still work in progress but hypoxia appears to 
lead to enhanced mitochondrial fusion which protects cells from apoptotic 
stimuli (Chiche et al 2010).  
Oxidative Stress – Whereas neurons succumb to persistent oxidative 
stress, chronically elevated ROS level appears to be a characteristic feature of 
tumor cells and is thought to be a way by which cancer cells evade death by 
anoikis (Pervaiz & Clement 2007). It is increasingly clear that ROS are 
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involved in tumor initiation, progression, and maintenance as well as in 
invasion. Thus, neurodegeneration in PD and cellular hyperproliferation in 
cancer appear to involve similar mechanisms. Not surprisingly, emerging 
evidence also suggest an extraordinary overlapping of genes involved in these 
two disparate disorders. 
 
1.15 PD-linked Genes and Cancer 
Hitherto, epidemiological studies linking cancers to specific PD-linked 
genetic mutation have not been performed, probably due to formal concerns 
over the small sample size involved. Nonetheless, tempting results pointing 
towards the contribution of PD-linked genes in cancers have been derived 
from various studies (Table 1.3). Below is a brief discussion of our present 
knowledge regarding the relationship between PD-linked genes and cancer. 
 
Table 1.3 PD-linked genes and their putative roles in cancers 
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α-synuclein – Although α-synuclein expression is restricted in the peripheral 
tissues, its level is apparently enhanced in abnormal cells. For example, under 
normal circumstances, ovarian tissue does not show immunoreactivity for α-
synuclein and its transcript is not detectable via Northern blotting. However, 
α-synucleins are expressed in 58% of ovarian carcinomas and low transcript 
levels of α-synuclein could be detected in several ovarian-derived tumor cell 
lines (Bruening et al 2000). Despite these observations, the role of this protein 
in ovarian carcinomas remains obscure. 
 
DJ-1 - Prior to its association with PD, DJ-1 was identified as a novel 
oncogene capable of transforming mouse fibroblasts in cooperation with H-ras 
(Nagakubo et al 1997). In addition, several reports have demonstrated a role 
for DJ-1 in human tumorigenesis. In breast cancer patients, elevated levels of 
circulating DJ-1 and anti-DJ-1 autoantibodies have been detected when 
compared against healthy control subjects (Le Naour et al 2001).  Next, in 19 
out of 23 primary non-small cell lung carcinoma samples, DJ-1 protein levels 
are found to be elevated (MacKeigan et al 2003) and elevated DJ-1 transcript 
level correlates with a poor prognosis in Stage I lung cancer patients (Kim et 
al 2005). Increased levels of DJ-1 mRNA are also seen in lung cancer patients 
who do not carry mutations in the Ras oncogene. Together, these observations 
suggest that DJ-1 is crucial for tumor initiation in certain types of lung cancer. 
In addition, in vitro study showed that DJ-1 could inhibit the action of the 
tumor suppressor PTEN on the negative regulation of PI3K pathway which in 
turn led to increased Akt activation. In support of the aforementioned 
observation, DJ-1 expression in primary breast cancer samples correlates 
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positively with phospho-Akt immunoreactivity. DJ-1 therefore seems to 
promote oncogenesis through its collective ability to inhibit the function of 
PTEN and promote cellular survival via the PI3K/Akt pathway (Kim et al 
2005). 
 
PINK1 - Before its association with autosomal-recessive early-onset PD, 
PINK1 was initially uncovered as a down-regulated gene product in PTEN-
deficient cancer cells (Unoki & Nakamura 2001). Following the restoration of 
PTEN levels in these cells, the expression of PINK1 is enhanced, suggesting 
that PINK1 is regulated by PTEN. The upregulation of PINK1 by the tumor 
suppressor PTEN therefore implicates its participation in cancer. Interestingly, 
a recent finding provides evidence for a dual role of PINK1, both as an anti-
apoptotic and a cell growth suppressive molecule, in breast tumorigenesis 
(Berthier et al 2011). In addition, a number of somatic mutations in PINK1 
have been identified in tissue samples from patients with various tumors 
although the pathological effects of these mutations are not known at present. 
Thus, the exact role of PINK1 in tumorigenesis remains to be determined. 
 
LRRK2 - At present, very little is known about the role of LRRK2 in 
tumorigenesis. However, PD patients who are of Ashkenazi Jewish origin and 
carrying LRRK2 G2019S mutation were found to have a concomitant higher 
risk for non-skin cancer than non-carrier patients with PD. Hence, LRRK2 may 
be a non-skin cancer predisposing gene (Inzelberg et al 2012). Interestingly, 
there is recent speculation that LRRK2 might be a member of the RIP 
(Receptor-interacting protein) kinase family of proteins, which has been 
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demonstrated to function as sensors of cellular stress. These kinases are 
involved in the integration of upstream signals to initiate a few specific 
responses, including cell-survival, inflammation or apoptosis, depending on 
the downstream mediators such as JNK, ERK, p38 and NF-κB (Declercq et al 
2009; Meylan & Tschopp 2005; Zhang et al 2010). It is possible to envisage 
therefore, that abnormal phosphorylation activity or aberrant phosphorylation 
of LRRK2 could lead to inappropriate stimulation of downstream effectors 
that elicit undesirable cellular responses, including cancers.  
 
PLA2G6 - A single nucleotide polymorphism (SNP) within an intron of 
PLA2G6 was found in a recent genome-wide association study (GWAS) to 
have a strong association with an increased risk in developing melanoma 
(Falchi et al 2009). Further evidence for its role in tumorigenesis was provided 
by another study that carried out pathway-based evaluation of candidate genes 
that may be involved in lung cancer. Interestingly, PLA2G6 was identified to 
be a lung cancer susceptibility gene (Hosgood et al 2008).  
 
1.16 Parkin and its Potential Role in Cancer 
 Similar to the PD-linked genes above, parkin dysfunction is also 
implicated in cancer. Recently, numerous characterization studies have shown 
that parkin is localized within the common fragile site (CFS) of chromosome 
6, FRA6E (6q26) (Cesari et al 2003; Denison et al 2003). CFSs are specific 
chromosomal loci that are prone to forming gaps and/or breaks on metaphase 
chromosomes after partial inhibition of DNA synthesis. Incidentally, FRA6E 
is the third most frequently observed CFS in the human population where it is 
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commonly deleted in several tumor types (Denison et al 2003; Smith et al 
1998). Microcell-mediated transfer of human chromosome 6 was shown by 
one group to suppress tumorigenicity in two breast cancer cell lines and 
several melanoma cell lines (Negrini et al 1994). Similarly, introduction of an 
intact human chromosome 6 into tumor-derived cell lines was able to restore 
senescence in these cells and also sensitize them to inhibitors of cell-cycle 
progression, suggesting the presence of a putative TSG residing on this 
chromosome. The residence of parkin on FRA6E immediately implicates its 
potential involvement in cancers as a potential tumor suppressor. Consistent 
with this, Cesari et al as well as a number of other groups have documented 
parkin gene alterations and concomitant reduction in parkin transcript 
abundance in a wide variety of cancers that includes breast, liver, non-small 
cell lung and ovarian carcinoma (Cesari et al 2003; Denison et al 2003; 
Picchio et al 2004; Wang et al 2004). In addition, stably-expressed wild-type 
parkin in hepatocellular carcinoma cell lines, where parkin is absent or 
reduced, resulted in significant reduction of their growth rate in vitro as well 
as sensitizing them to the effects of cell cycle/ HDAC inhibitors trichostatin A 
and sodium butyrate (Wang et al 2004). Apart from loss-of-heterozygosity 
(LOH) accounting for the observed reduction or alteration in parkin transcript 
levels, epigenetic downregulation of parkin has also been reported. Abnormal 
hypermethylation in the common PARK2 and PACRG promoter has been 
associated with downregulation of parkin expression in acute lymphoblastic 
leukemia and chronic myeloid leukemia (Agirre et al 2006). More recently, 
somatic mutations in parkin were discovered following an extensive exonic 
sequencing of the entire gene in 242 human cancer samples; including 
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gliobastoma, lung cancer and colon cancer (Veeriah et al 2010). Notably, these 
somatic missense mutations were found to cluster within the same domains 
and sometimes sharing the same residue as those PD-associated germline 
mutations. However, unlike in PD where it is generally thought that loss of 
two copies of the gene is needed for disease manifestation (Klein et al 2007); 
most parkin alterations in cancer are heterozygous in nature, suggesting that 
inactivation of a single copy is enough to confer a growth advantage. 
Notably, if the tumor suppressive activity of parkin is closely 
associated with its ubiquitin ligase activity, then one would expect an increase 
in parkin substrates that might have pro-mitotic roles. One such parkin 
substrate, as discussed earlier, is cyclin E, which is upregulated in ovarian, 
breast and other tumors (Courjal et al 1996; Mumberg et al 1997; Sewing et al 
1994). Interestingly, F-box/WD40 repeat protein 7 (Fbw7/Sel-10), a 
component of parkin-associated E3 ligase complex (Staropoli et al 2003), is 
occasionally mutated in various breast and endometrial tumors exhibiting 
increased cyclin E protein levels (Ekholm-Reed et al 2004; Spruck et al 2002). 
 Additional evidence in support of parkin as a potential tumor 
suppressor comes from a very recent finding which demonstrates a role for 
parkin as a target gene and downstream effector of the tumor suppressor, p53, 
in the regulation of glucose metabolism and the Warburg effect (Zhang et al 
2011). In this report, parkin was shown to contain p53 responsive elements in 
its promoter region as well as in intron 1 and is upregulated transcriptionally 
by p53, both in vitro and in vivo. Additionally, the authors demonstrated that 
p53 deficiency causes the Warburg effect, which was characterized by a higher 
rate of glucose uptake, higher rate of glycolysis and higher lactate production. 
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This phenomenon however, was reversed following ectopic parkin expression 
in p53-siRNA knockdown cells. By contrast, reduced or ablated parkin 
expression led to decreased expression of mitochondrial proteins which in turn 
contributed to reduced mitochondrial respiration and the promotion of the 
Warburg effect. Perhaps the role of parkin in regulating the Warburg effect 
can be attributed to the current proposed mechanisms by which parkin 
regulates mitochondrial function and homeostasis; including activating 
mitophagy in the clearance of damaged mitochondria (Geisler et al 2010a), 
promoting mitochondria fission (Deng et al 2008) and maintaining 
mitochondrial genome integrity (Suen et al 2010). The tumor suppressive 
function of parkin seems therefore, to be intricately connected to its ability to 
regulate mitochondrial homeostasis and in turn preventing the Warburg effect. 
Further to its ability in regulating mitochondrial function, parkin was also 
found to contribute to the role of p53 in protecting cells against oxidative 
insults by upregulating levels of reduced glutathione (GSH) and reducing 
levels of ROS. Oxidative stress is thought to play an important role in 
tumorigenesis by creating the proinflammatory microenvironment conducive 
for cellular transformation and as such, the antioxidant function of parkin 
should contribute immensely to its role in tumor suppression. It is interesting 
to note that the maintenance of mitochondrial homeostasis and regulation of 
oxidative stress are also important to the survival of neurons in PD, in which 
parkin also plays a pivotal role in. Together, these highlight therefore, the 
existence of overlapping pathways in both diseases and insights gained from 
understanding their common pathogenic mechanisms may improve the ways 
both diseases are currently being treated. 
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In summary, these data are in support of parkin as a putative TSG 
where its deficiency or dysfunction may contribute to tumorigenesis in 
mitotically active cells but degeneration in post-mitotic neurons as in the case 
of Parkinson’s disease. 
 
1.17 Rationale of Project Work 
  Given the importance of parkin function in maintaining cellular 
homeostasis relevant to both PD and cancer, I was motivated at the start of my 
Ph.D. program to understand how parkin function is regulated in vivo. To 
identify novel parkin interactors, I carried out a yeast two-hybrid screen using 
a human brain-derived cDNA library but to my surprise, I isolated a breast 
cancer related protein (BCA3/AKIP1) as a novel interactor of parkin. 
Prompted by this finding, and the intriguing relationship between PD and 
cancer, I went on to characterize the potential role of parkin in breast cancer 
and demonstrated that parkin acts as a tumor suppressor that negatively 
regulates the proliferation of breast cancer cells (Tay et al., 2010 J. Biol. 
Chem.). At the same time, I also characterized the relationship between parkin 
and the novel BCA3 interactor, which turned out to be complex. A synopsis of 
these two projects is given below, details of which are presented in Chapters 3 




I. Characterization of the putative role of parkin in breast cancer 
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 As discussed above, the recent mapping of the parkin gene to the 
common fragile site, FRA6E, which is frequently deleted or rearranged in 
several tumor types, suggests its involvement in cancers. The first part of my 
thesis thus investigates this possibility. In essence, I have demonstrated that 
parkin expression in a variety of breast cancer cell lines was dramatically 
down-regulated. Importantly, I showed that restoration of parkin expression in 
a representative parkin-deficient line mitigated its proliferation rate both in 
vitro and in vivo, as well as reduced the capacity of these cells to migrate. 
Related to this, I further found a hitherto unknown relationship between parkin 
and cyclin dependent kinase 6 (a cell cyle-related protein) - the expression of 
these two proteins appeared to be co-regulated. Interestingly, a recent study by 
Lucas et al (2004 Mol. Cancer Res.) demonstrated that CDK6 restrained the 
proliferation of breast cancer cells. Taken together, my results provided 
unambiguous support for a negative role of parkin in cancers as well as 
suggested a potential mechanism by which parkin exerted its tumor 
suppression function. 
 
II. Isolation and characterization of AKIP1/BCA3 as a novel parkin 
interactor 
By means of yeast two-hybrid screening, I have isolated a novel parkin 
interactor, BCA3/AKIP1, which has previously been characterized as a breast 
cancer-associated protein. The second part of my thesis thus examined the 
potential reciprocal functional effects that parkin and BCA3/AKIP1 exerted as 
a result of their interaction. Briefly, I found that BCA3/AKIP1 was not 
ubiquitinated by parkin thus excluding it as a substrate of parkin. Rather, their 
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interaction resulted in the promotion of BCA3/AKIP1 stability by parkin in a 
catalytically-independent manner. Notably, parkin did not promote 
BCA3/AKIP1 stability per se, but in fact, determined the cellular localization 
of BCA3/AKIP1 by promoting its nuclear occupation thereby prolonging the 
protein half-life of its interacting partner indirectly. It is unclear presently, 
with regards to the physiological function behind the nuclear promotion of 
BCA3/AKIP1 localization by parkin, although aggregated BCA3/AKIP1 
could apparently compromise the ability of parkin to clear damaged 
mitochondria. My results therefore, provided a functional relevance for 
BCA3/AKIP1 and parkin interaction and demonstrated the possibility of a 
pathogenic outcome in the event whereby catalytic function of parkin was 
compromised.  
 Collectively, the results presented, would help to refine our current 
understanding of the role of parkin in both neurodegeneration and 
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CHAPTER 2 
 




The pCDNA3-FLAG parkin expression construct was a kind gift from 
Professor R. Takahashi of Kyoto University. The parkin mutant, pcDNA3-
FLAG T415N was created by site-directed mutagenesis using the wild-type 
construct as a template. Wild-type parkin lentiviral construct was subcloned 
from the pcDNA-FLAG parkin (Takahashi) using HindIII restriction enzyme 
digestion followed by Klenow fill-in and then ApaI digestion and inserted into 
EcoRV and ApaI digested pL6mCW lentiviral vector. Parkin shRNA lentiviral 
construct (sc-42158-SH) and scrambled control shRNA constructs Plasmids-
A, B, C (sc-108060, sc-108065, sc-108066, respectively) were purchased from 
Santa Cruz Biotechnology. Plasmids expressing myc-tagged AKIP1a and its 
smallest isoform, 1c were amplified from SH-SY5Y cDNA by means of PCR 
and cloned into SalI and XhoI sites of the pCMV-myc vector. The myc-tagged 
BCA3/AKIP1 deletion constructs 1-101 and 102-210 were created by PCR 
amplification using myc-AKIP1a as template and cloned into pCMV-myc 
vector. The GST-Parkin deletion constructs, UBL-linker regions of parkin and 
R1-IBR-R2 region of parkin were generated separately from wild-type FLAG-
parkin cDNA by PCR amplification and subsequently cloned in-frame into 
pGEX-KG or the mammalian expression vector, pCDNA3-FLAG. Myc-
tagged synphilin-1, HA-tagged ubiquitin wild type, HA-tagged HHARI, HA-
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tagged c-Cbl, myc-tagged siah-1 and FLAG-tagged parkin missense mutants, 
C441R and G328E, have all been previously described (Chung et al 2001; 
Wang et al 2005b; Zhang et al 2000). HA-tagged SENP8 was commercially 
acquired from Capital Biosciences. 
 
2.1.2 Antibodies 
The following antibodies were used: polyclonal anti-parkin (Cell Signalling 
Technologies), monoclonal anti-parkin (clone PRK8) (Covance), monoclonal 
anti-FLAG peroxidase conjugate (Sigma), monoclonal anti-c-myc and anti-
HA peroxidase conjugates (Roche), monoclonal anti-β-actin (Sigma), 
monoclonal anti-FLAG (Sigma), polyclonal anti-c-myc (Bethyl Laboratories), 
FITC-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories 
Inc.), FITC-conjugated anti-rabbit IgG (BD Biosciences), rhodamine-
conjugated anti-mouse IgG (Molecular Probes), monoclonal anti-ubiquitin 
(clone FK2) (BIOMOL), polyclonal anti-AKT, polyclonal anti-pJNK and 
polyclonal anti-JNK (Cell Signalling Technologies), monoclonal anti-MBP 
(New England Biolabs), polyclonal anti-lamin (Santa Cruz Biotechnology), 
mouse polyclonal anti-BCA3/ C11orf17(B01P) (Abnova).  
 
2.1.3 Reagents 
Minimal synthetic dropout base, synthetic dropout supplements, yeast extract 
peptone dextrose were purchased from Clontech. Fetal bovine serum (FBS) 
and other cell culture reagents were from Invitrogen. Protein-G-Plus/A 
agarose was from Calbiochem, and enhanced chemiluminescence reagents 
were obtained from Amersham Biosciences. Puromycin was purchased from 
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Clontech to which a 100mM stock solution (in H2O) of puromycin was 
prepared and stored at -20oC. All other reagents were purchased from Sigma 
unless otherwise stated.  
 
2.2 Methods  
2.2.1  Real-Time PCR 
Total RNA was isolated from various breast cancer cells using the RNeasy 
Mini Kit (Qiagen). Subsequently, the isolated RNA was reverse transcribed 
using the Superscript First-Strand Synthesis System (Invitrogen). Real-Time 
PCR was carried out in a Light Cycler (Roche) using the FastStart DNA 
Master Plus Sybergreen I system (Roche) according to manufacturer’s 
protocol. Primers specific to our genes of interest were generated as follows: 
parkin-specific primers (Forward: 5’-GGAAGTCCAGCAGGTAGATCA; 
Reverse: 5’-ACCCTGGGTCAAGGTGAG), PINK-1 specific primers 
(Forward: 5’-TGCAGGGCTTTCGGCTGGAG; Reverse: 5’-
TCCTGGTGCACTGGTACCTG), DJ-1 specific primers (Forward: 5’-
AGTCTGCTGCTGTGAAGGAG; Reverse: 5’-
AGCAAGAGGGTGTGTTGTAAC). Concurrently, Real-Time PCR with a 
primer pair specific to GAPDH (Forward: 5’-
GAAGGTGAAGGTCGGAGTCAACG; Reverse: 5’-
TGCCATGGGTGGAATCATATTGG) was also included in the same run as 
an internal control. Statistical significance was determined using Student’s 
paired t-test for all comparisons (*P < 0.05, **P < 0.01). 
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2.2.2 In vivo Mouse Xenograft Flank Tumor Model 
All procedures involving animals were approved by and conformed to the 
guidelines of our Institutional Animal Care Committee. 6 week-old NOD-
SCID/J or Balb/c nude mice were allowed to acclimatize for 2 weeks before 
the start of the experiment. Each mouse was anaesthesized before being 
injected subcutaneously into the right rear flank with 100µl of PBS alone (as a 
control) or containing 3 x 106 MCF7-vector or MCF7-parkin stable cells. 
Tumor formation in injected mice was monitored daily. Where visible tumor 
was formed, its length (L) and width (W) were measured and the tumor 
volume, i.e. L x W2/2, subsequently calculated.  
 
2.2.3 Wound Scratch Migration Assay 
5 x 105 MCF7-vector or MCF7-parkin stable cells was seeded in 35 mm 
culture dishes and allowed to grow till about 90% confluency. A wound line 
was then made by scratching the cell monolayer with a pipette tip, gently but 
firmly. The cells were washed at least three times to remove debris before 
recovery in normal growth medium with reduced FBS (1%), to help curb 
proliferation rate. Photos were then taken at different sites along the scratch 
line (at least 3 fields) as baseline distance. The migration of cells into the 
wound area was monitored at a 12 h interval under a light microscope for a 
period of 84 h and photos were taken along the same sites. The migrated 
distance was calculated by subtracting the distance at the later time point from 
the distance at the baseline time point. Migration assay using the Matrigel 
transwell apparatus was conducted according to the instructions provided by 
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the manufacturer (BD Biosciences). Statistical significance was determined 
using Student’s paired t-test for all comparisons (*P < 0.05, **P < 0.01). 
 
2.2.4 Primary Breast Cancer Tissue Analysis 
Human breast cancer tissue qPCR array Panel I plate (OriGene Technologies) 
was removed from -20 oC storage and allowed to warm to room temperature. 
Master mix was prepared according to manufacturer’s protocol. The stock 
solution contains 2x QuantiTect SYBR Green PCR master mix, parkin 
forward and reverse primers, RNase-free water. 30µl of PCR pre-mix was then 
aliquoted to each of the 48 wells containing cDNA, and the plate was covered 
with adhesive cover sheet. The plate was then centrifuged at 800 g for 5 min 
and allowed to sit on ice for 15 min to allow the dried cDNA to dissolve. Real 
time PCR was done using the Applied Biosystems 7500 Real-Time PCR 
Systems, and the amplification condition is as follows: activation at 95 oC for 
15 min, followed by 40 cycles of denaturing at 94 oC for 15 s, annealing at 60 
oC for 30 s and extension at 72 oC for 60 s. The Ct value of the PCR products 
was obtained, and analysis was done. Automated immunohistochemistry was 
performed on 6 pairs of adjacent benign and malignant breast cancer tissues 
using the Leica Bond™ system using parkin antibody (1:500 dilution). Each 
breast tissue section was evaluated for parkin immunoreactivity using a semi-
quantitative scoring system based on the staining intensity. The 
immunoreactivity scores (IRS) were calculated as Σ (intensityn x percentage of 
positive stained cells with intensityn).  
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2.2.5 Cell Culture  
Normal human breast cells, Hs 578Bst (BST), were grown in Hybri-Care cell 
culture medium (ATCC) containing 10% FBS and 30 ng/ml of recombinant 
human epidermal growth factor (EGF). All other cell lines used in our 
experiments were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% FBS and 100 units/ml of penicillin/streptomycin 
unless otherwise stated.  
 
2.2.6 Generation of Stable Cell Lines and Cell Proliferation Assays 
MCF7 cells stably expressing parkin or otherwise containing vector alone 
were generated by transfecting 2 µg of the appropriate constructs. Two days 
later, the transfected cells were reseeded at a density of 1 x 106 cells per 10 cm 
culture dish, allowed to grow for one day before selecting for stably 
expressing cells by changing the media to one that contains 800 µg/ml of 
geneticin (Invitrogen). Subsequently, at least 20 clonal colonies were picked 
for each cDNA construct and screened by means of western blot analysis. All 
positive cell lines used for the experiments described hereafter were 
maintained in complete DMEM media supplemented with 200 µg/ml of 
geneticin to prevent extrusion of the integrated constructs. A simple 
population growth assay was conducted by seeding cells to be counted in 
duplicates at a concentration of 2x104 cells in 6-well plates, and subsequently 
quantifying their number each day for a period of 5 days by means of a 
haemocytometer. BrdU-based proliferation assay (Roche) was carried out 
according to manufacturer’s instructions. For soft-agar colony formation, 0.3% 
agar containing 1 x 104 MCF7-vector or MCF7-parkin stable cells was 
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overlaid onto pre-cast 0.5% bottom agar and allowed to solidify before 
incubating at 37oC in a 5% CO2 incubator for a period of 21 days. Colonies 
formed on the soft agar were visualized under light microscopy before and 
after MTT staining (Roche). Statistical significance was determined using 
Student’s paired t-test for all comparisons (*P < 0.05, **P < 0.01). 
 
2.2.7 Transfections, Preparation of Cell Lysates and Western Bot 
Analysis 
Cells were transiently transfected with various expression vectors using 
LipofectAMINE PLUS reagent (Invitrogen) according to manufacturer’s 
instructions. Two days later, transfected cells were lysed in PBST buffer (1% 
Triton X-100, 10 µg/ml aprotinin and 1 mM PMSF in PBS), sedimented at 
125,000 g for 15 min at 4 oC. The supernatants were collected as the Triton-X-
soluble fractions (S), while the pellets were washed once with PBST buffer 
before further extraction with SDS buffer (1% SDS in PBS). To properly 
resolve the pellets, they were sonicated briefly for 3 times, 15 s each time, 
before sedimenting at 125,000 g for 15 min at room temperature. Supernatants 
were collected as the SDS fractions (P). For certain experiments where levels 
of various phosphorylated protein species were analysed, cells were lysed with 
PBST containing phosphatase inhibitors cocktail 1 and 2 (Sigma-Aldrich) 
before sedimenting at 125,000 g for 15 min at 4 oC, using an ultracentrifuge 
and the rotor TLA 100.3 (Beckman). Only the supernatants were collected. 
For all experiments, equal amount of proteins were resolved on SDS-PAGE 
and the various ectopically expressed protein levels were analyzed by means 
of western blotting techniques using ECL detection reagents (Amersham).  
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2.2.8 Lentivirus Transduction of Cell Lines 
Virus production was performed in 293FT packaging cells using the 
packaging plasmids and following the protocols provided in the ViraPower 
Lentiviral Expression System (Invitrogen). Viral supernatant was concentrated 
by centrifugal ultrafiltration using Amicon Ultra-15 Centrifugal Filter Units 
(Millipore). Cells at 80% confluency were infected with concentrated virus 
supernatant in the presence of 6 µg/ml of polybrene. Selection for transduced 
cells was applied 3 days post-infection by supplementing culture medium with 
5 µg/ml of puromycin for 9 days. Once selection was complete, stable 
transductants were maintained in 2 µg/ml of puromycin. 
 
2.2.9 Microarray Analysis 
Total RNA was isolated from MCF7-vector and MCF7-parkin- stable cells 
using the RNeasy Mini Kit (Qiagen). RNA samples were then sent for 
microarray analysis using the Affymetrix GeneChip Human Gene 1.0 ST 
Array (Origen Laboratories Pte Ltd). For the experiments, 300 ng of total 
RNA was used for the hybridization process. Firstly, the arrays were washed 
and stained using the FS450_0007 fluidics protocol and then scanned using an 
Affymetrix 3000 7G scanner. Subsequently, the scanned images were 
inspected for hybridization efficiency and CEL files generated from GCOS 
(GeneChip Operating Software) were imported into Expression Console (EC) 
1.1 software for array quality control. Next, CEL files data from triplicates of 
MCF7 parkin and vector stables were analysed on the Biotique XRAY 
software.  Mixed ANOVA model with quantile normalization was employed 
for this purpose. Multiple Test Correction was done using Benjamini-
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Hochberg False Discovery Rate <0.005. Only results with a fixed factor 
absolute fold change of more than 1.5 fold were displayed. 
 
2.2.10 Yeast Two-hybrid Assay 
The bait vector was created by subcloning the unique linker region of human 
wild-type parkin (amino acids 77-237) into the two-hybrid bait vector 
pGBKT7 (Clontech) via PCR method using specific primers with restriction 
sites incorporated. The pretransformed human adult brain cDNA library 
subcloned into the prey vector, pACT2, was purchased from Clontech. Assays 
were performed according to the manufacturer’s protocol, using the 
Matchmaker Two-Hybrid System 3 (Clontech). Approximately a million 
independent transformants were plated onto nutritionally selective medium 
deficient in Ade, His, Leu and Trp. After incubating the plates at 30 °C for 5-
10 days, we carried out β-galactosidase filter lift assay for all the grown 
colonies, following which, colonies that turned blue were selected as positive 
clones. Yeast plasmids were isolated from these positive clones with lysis 
buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1% SDS) 
and retransformed into E. coli DH10B via electroporation. The plasmids were 
then amplified and isolated from DH10B for PCR using the FAD and RADO 
primers (refer to manufacturer’s protocol). Those that yielded PCR products 
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2.2.11 Subcellular Fractionation 
Cells were lysed in PBS containing 10 µg/ml aprotinin and 1mM PMSF, by 
firstly homogenizing them with 21 G needle for 18 strokes before sedimenting 
at 2600 g for 10 min at 4 oC. Supernatants from the initial sedimentation were 
collected and kept for further processing while the pellets were resolved in 
SDS buffer (1% SDS in PBS) and sonicate briefly, to give the pellet (P) 
fraction. The supernatants saved from the initial fractionation were further 
sedimented at 360,000 g for 1 h at 4 oC, using an ultracentrifuge and the rotor 
TLA 100.3 (Beckman). Supernatants from this step were collected as the 
cytosolic (C) fraction while the pellets were resolved in SDS buffer (1% SDS 
in PBS) and sonicated briefly, to give the membrane (M) fraction. Equivalent 
amount of proteins were resolved on SDS-PAGE and western blots were 
carried out as mentioned previously. 
 
2.2.12 Immunoprecipitation 
Two days after tranfection, cells cultured in 10 cm dishes were lysed in 
radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 
pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate and 1% 
Nonidet P-40. Cell lysates were centrifuged at 125,000 g for 15 min at 4 oC 
and supernatant fractions were incubated with antibodies overnight at 4 oC, 
followed by incubation with protein-G-PLUS/protein A agarose (Calbiochem) 
at the same condition for 2 h. Immunoprecipitates were washed five times with 
cell lysis buffer. Bound proteins were dissociated by boiling in 2X SDS 
sample buffer for 10 min, and whole protein samples were separated on SDS-
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PAGE. Western blots were carried out using the ECL method mentioned 
previously. 
 
2.2.13 Puromycin Pulse-chase  
HEK 293 cells were transfected with 0.25 µg of pcDNA3-BCA3 in the 
absence or presence of 0.25 µg FLAG-tagged parkin. Twenty-four hours post-
transfection, cells were washed and incubated with 0.1 mM of puromycin 
(Sigma), a protein synthesis inhibitor, in complete media for the indicated time 
points prior to harvesting in SDS buffer. The whole cell lysates were prepared 
and quantitated as described above. 
 
2.2.14 Immunocytochemistry and Confocal Microscopy 
5 x 104 of HEK 293 cells were seeded onto poly-D-lysine coated sterile 13mm 
round coverslips in a 24-well culture plate one day prior to transfection. After 
the cells were properly adhered, they were transfected with 0.25 µg of the 
desired constructs. 48 h post-transfection, the cells were washed once with 
PBS and fixed in 2.5% of paraformaldehyde (w/v), pH 7.4, overnight at 4oC. 
After fixing, the cells were washed twice in PBS before permeabilization with 
0.1% Triton X-100 (v/v) in PBS for 2 min. This was followed by incubation of 
primary antibodies, 0.2 µg per coverslip, in blocking agent, containing 5% 
fetal bovine serum (FBS), 1% horse serum and 1% bovine serum albumin 
(BSA), overnight at 4oC. Coverslips were washed in PBS three times before 
incubating in secondary antibodies, 0.2 µg per coverslip, in blocking agent for 
1 h at 25 oC in the dark. Cell nuclei were stained with Hoechst or DAPI for 10 
min, washed in PBS for five times before the coverslips were mounted onto 
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glass slides using FluorSave Reagent (Calbiochem). Immunofluorescent 
images were acquired on an Olympus confocal microscope. Negative controls 
omitting each primary antibody were performed in each case and no 
significant staining was seen (data not shown).  
 
2.2.15 Expression and Purification of GST-tagged Proteins 
The GST-tagged parkin or its deletion constructs were transformed into the 
modified E. coli strain BL21-CodonPlus (DE3)-RIL (Stratagene). An initial 
starter culture was prepared by inoculating a single colony into LB broth, 
containing 100 µg/ml (w/v) of ampicillin and grown at 37 oC, 220 rpm 
overnight. The next day, the starter culture was inoculated into a culture flask 
with LB broth containing, 100 µg/ml (w/v) of ampicillin and grown at 37 oC, 
220 rpm; till OD600 reached 1.0. Protein expression was then induced with 0.5 
mM of isopropyl-β-D-thiogalactopyranoside (IPTG) and the cells were 
cultured at 30 oC, 170 rpm, for another 3 h. Cells were pelleted by centrifuging 
at 6000 g for 10 min at 4oC and resuspended in 6 ml of ice-cold buffer, 
containing 1 ml of 10% Triton X-100, 2 µl of 200 mM PMSF, 2 µl of 1 M 
DTT and 20 µl of 10 mg/ml of aprotinin. Lysis of cells was carried out at 37 
oC for 10 min in the presence of 1 mg/ml of lysozyme. After chilling on ice for 
5 min, the lysate was sonicated five times for 30 s each time at 4 oC till they 
were not viscous. The rest of the purification was from hereafter, carried out in 
the cold. Sonicated cultures were centrifuged at 15,300 g for 30 min. 
Glutathione sepharose beads (Amersham) were washed three times in PBS and 
resuspended in a 1:1 suspension of glutathione beads/PBS. 1 ml of this 
resuspended slurry was added to supernatants collected from the spin and 
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rotated for 2 h. After incubation, the protein-bound beads were spun down and 
washed five times in 1% Triton X-100 (v/v) in PBS and used for pull-down 
assays. For storage, the beads were resuspended in a 1:1 suspension of 
PBS/glycerol containing protease inhibitors and kept at -20 oC. 
 
2.2.16 Purification of 6xHis-tagged Proteins 
6xHis-tagged BCA3 was transformed into the modified E. coli strain 
(mentioned previously). An overnight starter culture was grown at 37 oC, 220 
rpm. The next day, the starter culture was inoculated into a culture flask with 
LB broth containing 100 µg/ml (w/v) of ampicillin and grown at 37 oC, 220 
rpm; till OD600 reached 1.0. Protein expression was then induced with 0.5 mM 
of IPTG and the cells were grown at 30 oC for another 3 h. The cells were 
pelleted at 6000 g for 10 min at 4oC and resuspended in ice-cold lysis buffer 
consisting of 50 mM Tris-HCl pH 8.5, 100 mM KCl, 5 mM β-
mercaptoethanol, 1 mM PMSF and 1% (v/v) NP-40. All steps of the 
purification were carried out in the cold from hereafter. Cell lysates were then 
rotated for 15 min and centrifuged for 15 min at 15,000 g. Supernatant 
collected was loaded onto a column packed with ProBond resin (Invitrogen) 
and washed with Buffer A (20 mM Tris-HCl pH 8.5, 500 mM KCl, 20 mM 
imidazole, 5 mM β-mercaptoethanol, 10% (v/v) glycerol). The column was 
next washed with Buffer B (20 mM Tris-HCl pH 8.5, 1 M KCl, 5 mM β-
mercaptoethanol, 10% (v/v) glycerol). This was followed by another wash 
with Buffer A before proceeding to elution with Buffer C (20 mM Tris-HCl 
pH 8.5, 100 mM KCl, 100 mM imidazole, 5 mM β-mercaptoethanol, 10% 
(v/v) glycerol). If no elution is required, a final wash was performed with Tris-
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HCl buffer pH 8.5 containing 0.1 M NaCl. The ProBond resin was then 
resuspended in 1 ml of final wash buffer before being removed from the 
column for use in batch pull-down assay.  
 
2.2.17 Luciferase Assay 
HEK293 cells were cultured in 6-well plates and transfected with a luciferase 
reporter construct together with indicated plasmids using LipofectAMINE 
PLUS reagent (Invitrogen). Twenty-four hour after transfection, cells were 
stimulated with 10ng/ml of Phorbol 12 myristate 13-acetate (PMA) [Sigma] 
for 24 h and then assayed for luciferase activity using Ready-To-Glow 
Secreted Luciferase Reporter System according to manufacturer’s protocol 

















3.1  Overview 
 
As reviewed in the introductory chapter, mutations in the parkin gene, 
located on chromosome 6q25.2-27, are a predominant cause of inherited 
parkinsonism (Kitada et al 1998). Accordingly, much of the interest in 
characterizing the function of the parkin gene has been directed towards 
understanding its role in neurodegeneration. However, aberrant parkin 
function has also been linked to several other disorders (Mengesdorf et al 
2002; Mira et al 2004), amongst which, to the development of several types of 
cancers (Cesari et al 2003). Comparatively, the role of parkin in these 
disorders is less well understood. Supporting a role for parkin in cancers, 
Negrini et al have previously demonstrated that the introduction of an intact 
chromosome 6, which contains the 1.4 Mb parkin gene, into MCF7 (a breast 
cancer cell line) restores its ability to senesce (Negrini et al 1994). More direct 
evidence, however, came about a decade later from a study by Cesari et al., 
who via physical mapping and loss of heterozygosity (LOH) analysis showed 
that the 6q-located parkin is a frequent target of hemizygous deletion and 
inactivation in a variety of tumor biopsy samples, including those derived 
from breast cancers (Cesari et al 2003). Following this discovery, several other 
groups have similarly reported parkin gene alterations and expression 
variability in a variety of tumor biopsies and tumor cell lines representing a 
wide range of cancers including breast and ovarian cancers (Denison et al 
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2003; Picchio et al 2004; Veeriah et al 2010; Wang et al 2004). Collectively, 
these data support the existence of a tumor suppressor gene (TSG) on 
chromosome 6q and the candidacy of parkin as a TSG. Here, I investigated the 
potential involvement of parkin in the tumorigenesis of breast cancer. I 
demonstrated that the mRNA and protein expression of parkin were 
dramatically down-regulated in a variety of breast cancer cell lines compared 
with normal breast cells. Similarly, parkin expression was compromised in 
primary breast cancer tissues relative to adjacent normal tissues.  Further, I 
showed that restoration of parkin expression in a representative parkin-
deficient line, MCF7, mitigated its proliferation rate both in vitro and in vivo, 
as well as reduced the capacity of these cells to migrate. Cell cycle analysis 
revealed the arrest of a significant percentage of parkin-expressing breast 
cancer cells at the G1 phase. However, I did not observe significant changes in 
the levels of G1-associated cyclin D1 and E. On the other hand, the level of 
cyclin-dependent kinase 6 (CDK6) was dramatically and selectively elevated 
in parkin-expressing breast cancer cells, the extent of which correlates well 
with the expression of parkin. Interestingly, a recent study demonstrated that 
CDK6 restrained the proliferation of breast cancer cells (Lucas et al 2004). 
Taken together, my results support a negative role for parkin in tumorigenesis 
and provide a potential mechanism by which parkin exerts its suppressing 
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3.2  Results 
3.2.1 Aberrant parkin expression in several breast cancer cell lines 
As an initial effort to characterize the role of parkin in breast cancer, I 
examined the expression level of parkin in a number of commercially 
available breast cancer cell lines including ZR75, MDA231, T47D, MCF7 and 
HST. Consistent with the observation by Cesari et al (Cesari et al 2003), I 
found that parkin mRNA and protein levels were significantly reduced in all of 
these tumor-derived cell lines compared to normal breast cells (BST) or to the 
non-tumor derived HEK293 cell line (Fig. 3.1A & B). On the other hand, 
neither DJ-1 nor PINK1, representing two other PD-linked genes, exhibited a 
consistent pattern of down-regulation in this spectrum of breast cancer cells 
(Fig. 3.1A). 
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Figure 3.1 Parkin expression is down-regulated in breast cancer cells. (A) Bar-
graph depicting the real-time quantification of (top) parkin, (middle) DJ-1, (bottom) 
PINK1 mRNA levels in various breast cancer cell lines and in a normal breast cell 
line Hs578BST (BST). The non tumor-derived HEK 293 cells were used as an 
additional control. (B) Representative anti-parkin immunoblot showing the relative 
expression of endogenous parkin protein in various lines. The blot was stripped and 
reprobed with anti-actin to reflect loading variations. 
 
To extend these findings, I also examined the expression of parkin in primary 
breast cancer samples with the help of Ms. Chua Pei-Jou from Professor Bay 
Boon Huat’s laboratory (NUS Anatomy). Quantitative PCR analysis of 5 
identical sets of 48 tissues revealed that parkin expression was significantly 
lower in tumor compared to adjacent normal tissues (Mean Ct value: normal 
35.28 +/- 0.30 versus tumor 36.71 +/- 0.26), which is in agreement with our 
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earlier observations with cancer cell lines (Fig. 3.2A). Further, we also 
examined via immunohistochemical analysis whether parkin protein 
expression may be different between benign and malignant tissues. Although 
we recorded no difference in epithelial parkin expression between these 
tissues, the expression of stromal parkin in malignant tissues was apparently 
greatly reduced compared to their benign counterparts (Fig. 3.2A & B). Taken 
together, our results suggested that the function of parkin in breast cancer cells 
may be compromised via its down-regulation. 
 
 
Figure 3.2 Parkin expression is also down-regulated in primary breast cancer 
tissues. (A) Graphs showing the Ct value of parkin expression in normal and cancer 
tissues (left panel), and parkin immunoreactivity scores derived from 6 pairs of 
adjacent benign and maliganant breast cancer tissues. (B) Representative images 
showing immunohistochemistry staining of parkin in benign and malignant breat 
tissues, as indicated. Parkin is expressed in both stromal area and epithelial cells in 
breast. The stromal staining in benign breast tissue is higher as compared to 
malignant breast tissue. All samples were counterstained with hematoxylin. Statistical 
analysis was carried out using GraphPad Prism, Version 4.0 software. Wilcoxon 
matched pair test was used to compare the difference between adjacent benign and 
malignant breast tissues (*, p<0.05). 
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3.2.2 Ectopic parkin expression in parkin-deficient MCF7 breast cancer 
cells mitigates their proliferation in vitro 
  To examine the effects of restoring parkin expression in parkin-
deficient breast cancer cells, I generated stable clones of MCF7 cells 
expressing FLAG-tagged parkin (MCF7-PK) or containing vector alone as a 
control (MCF7-Vector). The MCF7 cell line was selected for this study 
because it is a widely used in vitro model of breast cancer and also one that is 
highly deficient in parkin expression (Fig. 3.1A & B). Three individual parkin-
positive MCF7 clones (#5, 7 and 11) were selected for experimentation to 
minimize clonal variation. Notably, all of these parkin-positive clones express 
parkin at a higher level than vector control or parental cells (Fig. 3.3A), but are 
otherwise similar morphologically (not shown). A simple population growth 
assay revealed that the proliferation rate of parkin-expressing MCF7 cells was 
significantly reduced compared to control cells (Fig. 3.3B, left).Interestingly, 
the rate of reduction did not correlate with the expression levels of parkin, 
suggesting that although ectopic parkin expression in MCF7 cells mitigated 
their growth, the decrease in proliferation rate was apparently dependent on 
the presence of a low threshold level of parkin expression (beyond which there 
appeared to be no additional effect). Supporting this, siRNA-mediated 
depletion of parkin expression in these stable clones reversed the inhibitory 
effects of parkin on their proliferation rate (Fig. 3.3B, right). Similarly, the 
incorporation of BrdU, a thymidine analogue, in parkin-expressing MCF7 
cells also occured significantly less frequently compared to control cells in 
both groups of MCF7 stables that were generated via two different 
approaches, namely, lipofection-based and lentiviral-based deliveries (3.3C); 
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thus representing different methods of clonal derivation. The ability of parkin 
to suppress the proliferation of MCF7 cells appeared to be dependent on its 
catalytic activity, as MCF7 cells stably expressing a catalytically-impaired 
parkin mutant (T415N) did not exhibit any alterations in their proliferation rate 




Figure 3.3 Overexpression of parkin in MCF7 cells mitigates their proliferation 
rate. (A) Anti-FLAG and anti-parkin immunoblots of total lysates prepared from 
MCF7 cells (-), vector control (V) and the parkin-expressing stable clones (#5, 7 & 
11) derived by means of lipofectin-based approach. (B) Graphical depiction of the 
percentage of cells undergoing cell proliferation, as measured by cell population 
number, in MCF7 vector control and parkin-expressing stable cell lines (left), or 
parkin-expressing cells in the presence of control or parkin siRNA (Kipp et al). (C) 
BrdU assay of MCF7 vector control and parkin-expressing stable cell lines (left). 
Anti-FLAG immunoblots of MCF7 vector control and parkin-expressing stable cell 
lines derived by means of lentiviral approach (middle) and graphical depiction of the 
percentage of these lentiviral-derived stable cells undergoing proliferation, as 
measured by BrdU assay. (D) As in (C), graphical depiction of BrdU assay of MCF7 
vector controls (n=2, i.e. an average of two vector clones performed in triplicates) and 
parkin T415N mutant-expressing stable cell lines (n=4, i.e. an average of four 
lentiviral clones performed in triplicates). 
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 Since cancer cells are anchorage-independent and have the ability to 
form colonies in soft agar, I also examined whether ectopic parkin expression 
in MCF7 cells compromised its ability to generate colonies in soft agar. I 
found that the number of soft agar colonies formed by parkin-expressing 
MCF7 cells was dramatically reduced and the size of these colonies also 
tended to be smaller compared to those generated by control MCF7 cells (Fig. 
3.4, not shown for MCF7-parkin #7 and #11).   
 
Fig. 3.4 Ectopic parkin expression in MCF7 cells compromise its ability to 
generate colonies in soft agar. Representative images showing apparent decreased 
ability of parkin expressing MCF7 cells in forming colonies in soft agar compared to 
MCF7-vector control. 
 
3.2.3 Ectopic parkin expression in parkin-deficient MCF7 breast cancer 
cells mitigates their proliferation in vivo 
To extend the above findings, I recruited the help of a fellow 
laboratory  colleague (Mr. Calvin Yeo WS) to examine the effects of parkin 
over expression on the ability of MCF7 cells to generate solid tumor in vivo. A 
flank tumor model (n = 9 for each group), where NOD-SCID mice were 
injected subcutaneously with parkin expressing or control MCF7 cells, or 
otherwise with PBS alone, was used for this purpose. Over a period of four 
weeks post-injection, we observed visible tumor formation that progressively 
increased in size in mice injected with control or parkin-expressing MCF7 
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cells, but not in those injected with vehicle alone (Fig. 3.5, not shown for PBS 
control). Consistent with my in vitro findings above, we found that parkin-
positive clones tended to generate tumors of significantly smaller volume and 
mass in vivo compared to control cells (Fig. 3.5A, B & C). In addition to using 
NOD-SCID mice, we also duplicated the experiment in athymic nude mice 
(n=6) by carrying out the experiment as previously described. The athymic 
nude mice also gave us similar results to that of the NOD-SCID flank tumor 
model (Fig. 3.6). Taken together, our findings demonstrated that ectopic 
parkin expression in parkin-deficient MCF7 cells mitigated its proliferation 
both in vitro and in vivo, and strongly suggested a negative role for parkin in 
breast cancer cell proliferation. 
 
Figure 3.5 Parkin over-expression mitigates tumor formation in vivo in a NOD-
SCID mouse flank model. (A) Graphs showing the volume (left and middle panels) 
and mass (right panel) of tumor generated by different cells in NOD-SCID mice 
(n=9) at day 14 and 28. The experiment was duplicated with essentially the same 
result (*, p < 0.05; **, p < 0.001, Student’s t test). 
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Figure 3.6 Parkin over-expression mitigates tumor formation in vivo in an 
athymic nude mouse flank model . (A) Graphs showing the volume of tumor 
generated by different cell types in nude mice at day 5 and day 12. (B) Images 
showing the presence of macroscopic tumor in athymic nude mice 8 weeks post-
injection with MCF7 vector control cells, in contrast to those injected with MCF7 
cells stably expressing parkin. (C) Representative images showing (I) tumor section 
stained with H &E (Scale bar: 100 µM) and (II) a magnified portion of the tumor 














Putative Role of Parkin in Breast Cancer    76 
3.2.4 Ectopic parkin expression in parkin-deficient MCF7 breast cancer 
cells  reduces their migration rate.  
  I next asked the question whether ectopic parkin expression in parkin-
deficient MCF7 cells would influence their migration properties. To address 
this, I performed a simple wound scratch assay and monitored the re-
colonization process for 84 h (3.5 days). From 36 h onwards, I found that 
MCF7 cells ectopically expressing parkin migrated significantly slower into 
the scratched area compared to control cells (Fig. 3.7A & B). This trend 
persisted for all the parkin-expressing MCF7 clones until the end of the 
experimental period (Fig. 3.7A & B). Clearly, ectopic parkin expression in 
these cells markedly retarded their rate of migration.  
 
 
Figure 3.7 Parkin-expressing MCF7 cells exhibit slower migration. (A) Phase-
contrast images showing the re-colonization of cells into the wound area at 60 h. (B) 
Graphical depiction of the distance moved by the various cell types (as indicated) into 
the wound area. (*, p < 0.05, Student’s t-test). (C) Bar graph showing the ratio 
between parkin-expressing and control cells that migrated to the underside of the 
matrigel-coated transwell after 24 h of incubation (*, p < 0.05, Student’s t test). 
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To verify the observations above, I repeated our migration assay using 
the standard matrigel invasion chamber (see Materials and Methods). 
Consistent with my above findings, I recorded a significantly reduced ability 
of parkin-expressing MCF7 cells to migrate to the underside of the matrigel-
coated transwell compared to control cells (Fig. 3.7C, not shown for MCF7-
parkin #7 and #11). Taken together, my results suggested that ectopic parkin 
expression influenced the proliferation as well as migration properties of 
MCF7 breast cancer cells. 
 
3.2.5 Parkin promotes MCF7 cell cycle arrest at G1 phase 
Conceivably, the reduced proliferation rate of parkin-expressing MCF7 
cells may be due to alterations of its cell cycle program as a result of parkin 
over-expression. To examine whether parkin affects the cell cycle profile of 
MCF7 cells, I analyzed the cell cycle profile of control and parkin-expressing 
MCF7 cells by means of flow cytometry. Interestingly, compared to control 
cells, a significant number of parkin-expressing cells apparently accumulated 
at the G1 phase (Fig. 3.8). In agreement with this, the percentage of parkin-
expressing cells at the S and G2/M phases was markedly reduced relative to 
MCF-vector controls (Fig. 3.8). Collectively, these results suggested that 
parkin reduced the proliferation rate of MCF7 breast cancer cells by promoting 
their arrest at the G1 cell cycle phase. 
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Figure 3.8 Accumulation of parkin-expressing MCF7 cells at G1 phase. (A) 
Graphical depiction of flow cytometry-based cell cycle analysis of control and parkin-
expressing MCF7 cells. (B) Bar graphs showing the percentage of control (vector) or 
parkin-expressing MCF cells (parkin) in various phases of the cell cycle. 
 
 
3.2.6 No change in cyclin D or E expression in parkin-expressing MCF7 
cells 
Interestingly, cyclin E, a cell cycle regulator required for the transition 
from G1 to S phase, has previously been identified as a parkin substrate 
(Staropoli et al 2003). Parkin apparently ubiquitinates cyclin E and promotes 
its turnover. Moreover, recent studies demonstrated defects in cyclin E 
proteolysis in colon and brain cancer cells harboring dysfunctional parkin 
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(Dorsey et al 2007; Ikeuchi et al 2009). I was therefore interested to examine 
whether cyclin E expression is affected in parkin-expressing MCF7 cells. 
However, I did not detect an apparent difference in the steady state level of 
cyclin E between parkin-expressing and control MCF7 cells (Fig. 3.9A). Like 
cyclin E, cyclin D is also involved in G1 to S transition. Hence, I also 
examined its levels in parkin-expressing MCF7 cells. Similar to cyclin E, the 
expression of cyclin D was also not significantly affected in MCF7 cell stably 







Figure 3.9 Levels of Cyclin D & E remain unchanged in parkin-expressing 
MCF7 cells. (A) Anti-cyclin E and (B) anti-cyclin D1 immunoblots showing the 
levels of cyclin E and D respectively in vector control (V3) and parkin-expressing 
(PK5,7 & 11) MCF7 cells. Equal loading of the different lysates was verified by anti-
actin immunoblotting. 
 
3.2.7 Levels of activated Erk and Akt in parkin-expressing MCF7 cells 
 Conceivably, the expression of mitogenic components might differ 
between parkin-expressing and control MCF7 cells. A prime candidate central 
to mitogenic signaling is Erk (extracellular regulated kinase), which exists in 
several isoforms. Another is Akt, whose hyper-activation is linked to several 
tumor types. Among the Erk isoforms, Erk 1 and 2 are the main downstream 
effectors of mitogenic growth factor signaling. However, I failed to observe a 
clear trend in the level of activated, phosphorylated species of Erk 1 and 2 
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between parkin-expressing MCF7 cells and control cells (Fig. 3.10A). In 
contrast, the level of phosphorylated Akt appeared to increase, rather than 
decrease in parkin-expressing MCF7 cells compared to control cells (Fig. 
3.10B). It would thus appear that parkin-mediated suppression of MCF7 cells 
did not involve changes in the levels or activation of cyclin D1, E, Erk1/2 and 
Akt. Thus the mechanism underlying parkin-mediated suppression of breast 
cancer cell proliferation remains elusive, although my later studies have 







Figure 3.10 Levels of Erk and Akt in parkin-expressing MCF7 cells. (A) Anti-
phosphorylated and unphosphorylated Erk and (B) anti- phosphorylated and 
unphosphorylated Akt immunoblots showing the levels of Erk and Akt respectively in 
vector control (V3) and parkin-expressing (PK5,7 & 11) MCF7 cells. Equal loading 
of the different lysates was verified by anti-actin immunoblotting. 
 
3.2.8 Microarray analysis of parkin-expressing MCF7 cells 
Although the precise mechanism by which parkin mediates the 
suppression of MCF7 breast cancer cell proliferation is unclear, I reasoned that 
parkin likely participates in some cellular signaling events that trigger changes 
in the expression of specific genes, which in turn mediates its tumor 
suppression properties. I therefore subjected parkin-expressing and vector-
control MCF7 cells to microarray analyses using Affymetrix chips. Principal 
component analysis (PCA) plots of the data obtained revealed that the gene 
expression changes in the two groups of cells were significant (Fig. 3.11), 
Putative Role of Parkin in Breast Cancer    81 




In these analyses, the most significant alterations were a near 5-fold 
repression of the gene encoding the cysteine-rich secretory protein LCCL 
domain containing 1 (CRISPLD1) and a 3.4-fold upregulation of the gene 
encoding cyclin-dependent kinase 6 (CDK6) in parkin-expressing cells 
compared to control MCF7 cells (Fig. 3.12). Whereas CDK6 is a cell cycle-
related protein, less is known about the function of CRISPLD1 except that it 
belongs to the CAP (Cysteine-rich secretory proteins Antigen 5 and 
Pathogenesis-related proteins) superfamily that has roles in cancer and 







Figure 3.11 PCA plot. PCA plot of 
microarray data from parkin-
expressing and control MCF 7 breast 
cancer cells. Note that the clear 
segregation of the two groups of data. 
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Figure 3.12 Microarray analysis of gene expression changes in control and 
parkin-expressing MCF7 cells. (Top panel) Diagrammatic representation of the 
gene expression differences between parkin-expressing and control MCF7 cells. 
(Bottom panel) Top 10 induced (left) or repressed (Kipp et al) genes upon parkin 
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3.2.9 CDK6 expression is significantly enhanced in parkin-expressing 
MCF7 breast cancer cells 
Because CDK6 has been previously suggested to be involved in breast 
cancers, I was interested to validate its association with parkin. I next sought 
to address whether the increased CDK6 transcript levels would translate to an 
increase in protein expression. Consistent with the microarray analysis result, 
anti-CDK6 immunoblotting of lysates prepared from MCF7-vector and 
MCF7-parkin cells revealed a significant elevation of the protein in parkin-
expressing MCF7 cells (Fig. 3.13A). Importantly, the expression of CDK6 
correlated well with the level of parkin expression in the various stable clones 
(Fig. 3.13A). This relationship between parkin and CDK6 was clearly 
dependent on the catalytic activity of parkin, as substituting parkin with the 
catalytically-impaired T415N mutant failed to influence CDK6 expression 
(Fig. 3.13B).  Similarly, replacing parkin with CHIP, a related E3 member, did 
not affect CDK6 expression (Fig. 3.13C). 
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Figure 3.13 CDK6 expression is enhanced in parkin-expressing MCF7 cells. (A) 
Immunoblots showing the levels of CDK6 and parkin in control (vector) or parkin-
expressing MCF7 cells (left). Bar graph showing the relative differerence in CDK6 
expression among the MCF7 clones examined as determined by densitometric 
quantification. (B) Just as in (A), except that parkin is substituted with a catalytically-
impaired T415N mutants are indicated as TN2 and TN3. (C) Representative confocal 
images showing CDK6 staining in MCF7 cells transiently transfected with parkin or 
CHIP, as indicated. 
 
I also generated MCF7 cells stably expressing parkin R275Q and 
R275W, which are respectively associated with cancer and PD (Dorsey et al 
2007). Neither of these mutants altered CDK6 levels when expressed in the 
breast cancer cell line (Fig. 3.14A). Interestingly, the phenomenon appeared 
unique to breast cancer cells, as MCF7 cells transfected with increasing 
amounts of parkin cDNA showed a dose-dependent increase in CDK6 
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expression (Fig. 3.14B) while CDK6 expression in a different cell line, i.e. 
SH-SY5Y neuroblastoma cells that ectopically expressed parkin was 
unaffected (Fig. 3.14C). Taken together, my results demonstrated a hitherto 
unknown cellular co-regulation of parkin and CDK6 expression in breast 
cancer cells. Given the recently described role of CDK6 as a negative 
regulator of breast carcinogenesis (Lucas et al 2004), my results also 
suggested a potential mechanism by which parkin exerted its suppression on 




Fig. 3.14 Parkin mediated effect on CDK6 expression is catalytically-dependent 
and seems to be cell-type dependent. (A) Immunoblots showing the expression of 
CDK6 in MCF7 cells stably expressing the cancer-associated R275Q parkin mutant 
(left) and the PD-associated R275W parkin mutant (Kipp et al). (B) Transient 
overexpression of parkin in MCF7 cells in increasing amounts leads to a similar dose-
dependent effect in CDK6 expression. (C) Level of CDK6 remains unchanged in SH-
SY5Y cells transiently expressing increasing amounts of parkin. 
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3.3 Discussion 
 
Globally, breast cancer is the most prevalent cancer among women and 
is second only to lung cancer in women’s cancer mortality. The estimated 
annual incidence of breast cancer worldwide is a staggering one million cases. 
Closer home, the figures are equally of healthcare and social concern. One in 
five cancers occurring in Singaporean women is breast cancer. In a population 
of just four million, we have about 1000 new cases of breast cancer annually. 
This translates to about three women being diagnosed with breast cancer each 
day. About 260 die from the disease each year, and one in twenty women in 
Singapore will be diagnosed with breast cancer in their lifetime (Source: 
Singapore Breast Cancer Foundation). Clearly, a more accurate assessment of 
breast cancer risk will provide us a better opportunity to manage and treat the 
disease. As discussed in the introductory chapter, there is a curious and 
unexplained prevalence of breast cancer amongst PD patients. A provocative 
functional connection between these two seemingly disparate diseases is their 
collective dependence on a strict regime over the cell cycle program. 
Deregulation of the cell cycle responsible for tumorigenesis can elicit 
apoptosis in postmitotic neurons, resulting in neurodegeneration. Furthermore, 
emerging evidence suggests that PD-linked genes such as parkin, functionally 
connects brain neuronal degeneration with breast cell hyperproliferation.  
In this chapter, I have demonstrated that parkin expression is 
dramatically downregulated in a variety of breast cancer cell lines as well as in 
primary breast cancer tissues. Further, I showed that restoration of parkin 
expression in a representative parkin-deficient line mitigates its proliferation 
rate both in vitro and in vivo, as well as reduces the capacity of these cells to 
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migrate. Collectively, my results strongly support a role for parkin as a TSG. 
Although a role for parkin in cancers may still come as a surprise to many, the 
1.4 Mb parkin gene is located within the common fragile site (CFS), FRA6E, a 
mutational hotspot on chromosome 6 that is frequently deleted in several 
tumor types including breast, ovarian, kidney and liver cancers (Smith et al 
1998). FRA6E, along with other CFSs such as FRA3B, FRA16D and FRAXB, 
have been proposed to play a causal role in tumorigenesis and/or cancer 
progression (Smith et al 1998; Smith et al 2006). Notably, the FRA3B-
associated FHIT and the FRA16D-associated WWOX genes are commonly 
deleted or altered in various tumor types. Further, several lines of evidence 
suggest that functionally, FHIT and WWOX act as tumor suppressors 
(Bednarek et al 2001; Druck et al 1998; Ishii et al 2001). The residence on 
FRA6E that the enormous parkin gene takes thus immediately suggests its 
potential association with cancers. Consistent with this, Cesari et al as well as 
a number of other groups have documented parkin gene alterations and 
concomitant reduction in parkin transcript abundance in a wide variety of 
cancers that includes breast, liver, non-small-cell lung and ovarian carcinoma 
(Cesari et al 2003; Denison et al 2003; Picchio et al 2004; Wang et al 2004). 
Here, my results extended these findings by showing that parkin expression 
down-regulation in several breast cancer cell lines was rather specific to the 
gene as DJ-1 and PINK1 did not exhibit a consistent reduction in their 
expression in these cells.  
Despite a consistent association between parkin expression alterations 
and cancers, there is currently a paucity of reports that demonstrate robustly 
the functional consequence of parkin restoration in parkin-deficient cancer 
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cells, although a very recent study by Veeriah et al. showed that restoration of 
parkin expression in parkin-deficient glioma cells clearly mitigated their 
growth (Veeriah et al 2010). By means of a wide spectrum of proliferation 
assays that include population growth, anti-BrDU-staining, soft-agar colony 
formation as well as generation of solid tumors in NOD-SCID mice, I showed 
here that the restoration of parkin expression in MCF7 cells markedly reduced 
their proliferation rate both in vitro and in vivo, and significantly slowed down 
their migration. My results therefore provided further evidence supporting a 
tumor suppressor-like function of parkin. Mechanistically, how parkin 
suppresses the growth of MCF7 cells remains to be elucidated. Because parkin 
functions as a ubiquitin protein ligase and one of its identified substrates is 
cyclin E (Staropoli et al 2003), a G1 cyclin whose accumulation is associated 
with breast cancer development (Keyomarsi et al 1995), it is tempting to 
speculate that mis-regulation of cyclin E levels in parkin-deficient cells could 
promote tumorigenesis. However, I did not observe obvious difference in 
cyclin E levels between control and parkin-expressing MCF7 cells. Neither did 
I observe a significant difference in the levels of cyclin D1 between these two 
cell types. Further, I failed to observe any reduction in growth factor signaling 
via Erk1/2 activation in parkin-expressing MCF7 cells. Surprisingly, the 
growth promoting PI3/Akt signaling pathway appeared to be upregulated in 
MCF7 cells stably expressing parkin. This is intriguing given our observation 
that parkin negatively regulates MCF7 cell proliferation, although a correlative 
relationship between Akt activation and parkin expression has been previously 
reported by others (Fallon et al 2006; Ikeuchi et al 2009). Conceivably, a 
network of other players might be involved in parkin-mediated suppression of 
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breast cancer cell proliferation. In this regard, it is interesting to note that the 
microarray analysis have identified many interesting candidates whose 
expression is significantly altered in the presence of parkin expression. 
Amongst these is CDK6, whose expression increased by more than 3-fold in 
parkin-expressing relative to control MCF7 cells. Interestingly, Lucas et al 
have recently demonstrated that whereas normal human mammary epithelial 
cells contains high levels of CDK6 protein and activity, all the breast tumor-
derived cell lines examined exhibit significantly reduced levels of CDK6, with 
several having little or no CDK6 (Lucas et al 2004). Importantly, they showed 
that restoration of CDK6 in breast cancer cells restrained their proliferation 
(Lucas et al 2004). Similarly, NIH3T3 lines engineered to over-express CDK6 
all exhibit reduced rate of proliferation relative to parental control cells 
(Nagasawa et al 2001). It is thus attractive to speculate that enhanced CDK6 
expression in parkin-expressing MCF7 cells participates to mitigate the 
proliferation rate of these cells. Notwithstanding this, it is important to point 
out that the reported anti-proliferative role of CDK6 is non-classic and 
currently controversial. However, this paradoxical activity of CDK6 is not 
without precedent. For example, Stat3, a widely accepted oncogene, was 
shown recently to play a tumor-suppressive role in PTEN-deficient human 
glioblastoma cells (de la Iglesia et al 2008). It would therefore appear that the 
physiological manifestation of an oncogene (or tumor suppressor) is dependent 
on the cellular context. I have attempted to study the effects of CDK6 over-
expression in MCF7 cells. However, unlike Lucas et al. (Lucas et al 2004), I 
have difficulties analyzing MCF7 cells expressing exogenous CDK6 as they 
detach from cell culture substratum and round up readily (not shown), 
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suggesting that CDK6 expression above a certain threshold level potentially 
promotes apoptosis of MCF7 cells. Interestingly, the microarray analysis also 
revealed a significant downregulation of  a relatively novel protein known as 
CRISPLD1, a member of the  CAP superfamily that apparently has roles in 
cancer and immune response (Gibbs et al 2008). Although much less is known 
about the role of CRISPLD1 in breast cancer at this moment, future 
experiments should help elucidate the relationship between CRISPLD1 and its 
potential interaction with parkin in mediating the suppression of breast cancer 
cell proliferation.  
In essence, my results presented in this chapter strongly support a 
negative role for parkin in breast cancers, which likely involves a novel (albeit 
currently correlative) relationship between parkin and CDK6. 
 
 
Results presented in this chapter have been published in the  



















As discussed in chapter 1, a laundry list of parkin substrates has been 
identified to date. Notably, the functional characterization of these substrates 
has illuminated the cellular pathways that parkin participates in, and as a 
result, shed considerable mechanistic insights on how dysfunctional parkin 
could promote diseases like PD and cancer. In parallel, several regulators of 
parkin function have also been isolated. These include CASK/LIN-2 (Fallon et 
al 2002), CHIP (Imai et al 2002), Rpn10 subunit of the 26S proteasome 
(Sakata et al 2003), Bag5 (Kalia et al 2004), Nrdp1/FLRF (Zhong et al 2005) 
and 14-3-3η (Sato et al 2006). Depending on which of these proteins parkin 
interacts with, the function of parkin in the cell may be variously modified. 
For example, CHIP interaction with parkin apparently enhances its 
ubiquitination activity (Imai et al 2002), whereas the association of Bag5, 
Nrdp1/FLRF or 14-3-3η with parkin results in the opposite, i.e. reduction of 
parkin catalytic activity (Kalia et al 2004; Sato et al 2006; Zhong et al 2005). 
On the other hand, CASK/LIN-2 interaction with parkin does not affect its 
activity per se but rather promotes its localization to synaptic membranes 
(Fallon et al 2002). Given parkin’s dual role as a broad-spectrum 
neuroprotectant in the brain and as a tumor suppressor in many parts of the 
body, it is conceivable that aberrant regulation of parkin function by its 
various interactors could promote neurodegeneration or cancer. Supporting 
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this, adenovirus-mediated expression of Bag5 (a negative regulator of parkin 
function) in the SNpc of rats results in marked DA neurodegeneration (Kalia 
et al 2004).  
In this chapter, I described the isolation and characterization of 
BCA3/AKIP1, a novel interactor of parkin. BCA3/AKIP1 is a breast cancer-
associated protein that I have isolated by means of a yeast two-hybrid screen 
from a human adult cDNA brain library. Naturally, I was initially excited 
about having potentially discovered a link between neurodegeneration and 
breast cancer related to parkin. However, despite its clear interaction with 
parkin, BCA3/AKIP1 turned out to be neither a classical substrate nor 
regulator of parkin. Instead, parkin promotes the stability and nuclear 
localization of AKIP/BCA3 in a totally catalytically-independent manner. 
Although a ubiquitin ligase-independent function of parkin has recently been 
reported in the control of p53 transcription (da Costa et al 2009), this is the 
first description to the best of my knowledge that parkin can influence the 
stability and cellular localization of an interacting partner in a manner that is 
independent of its enzymatic activity. Moreover, under normal conditions, 
BCA3 expression does not appear to compromise parkin ubiquitination 
activity. However, under conditions when mitochondria become depolarized, 
BCA3 retards parkin-mediated removal of damaged mitochondria. Thus, the 
relationship between parkin and AKIP1 is much more complex than I have 
originally envisaged, although I remain optimistic that my findings will lead to 
a shift in the paradigm of parkin function that is relevant to both 
neurodegeneration and cancer. 
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4.2 Results 
4.2.1 Choice of bait 
Prior to the start of my research project, most of the reported findings 
on parkin interactors isolated via yeast two-hybrid screen were carried out 
using either full length parkin or its catalytic domain as bait. In many of these 
instances, the interactors often turned out to be parkin substrates. The results 
are highly reflective of the choice of bait. Since most of the baits contain the 
RING box catalytic domain, it is not surprising then that the preys isolated are 
usually substrates of parkin. Nonetheless, these studies were immensely 
informative, and they offer insights into the function of parkin as an E3 ligase 
and the roles played by the respective substrates in disease pathogenesis in 
relation to their interaction with parkin. In order to examine how aberrations in 
parkin regulation mediated by its non-substrate interactors could also 
contribute to pathology, we feel the need to identify regulators of parkin 
function rather than to isolate yet another substrate of the ubiquitin ligase. This 
was our original rationale for the study described here. The unique region of 
parkin was chosen as our bait of choice for two main reasons. Firstly, it is 
unique to parkin just as the name suggests, thus increasing the likelihood of a 
bona fide interaction. Secondly, the RING box domain is highly conserved in 
E3 ligases and by excluding it, it will increase the stringency of our interaction 
screen and also our chance of isolating a parkin regulator. 
 
4.2.2  Identification of BCA3/AKIP1 as a novel parkin interactor  
  To identify novel parkin interactors, I carried out yeast two-hybrid 
(Y2H) screening using the unique linker region (amino acids 77 – 237) of 
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parkin as bait against a human adult cDNA brain library. Of the several 
positive clones obtained on a quadruple dropout plate (-Ade; -His, -Leu, -Trp) 
(see Materials and Methods), two encoded variants of a protein known as 
BCA3 (Breast cancer-associated protein 3), a proline-rich breast cancer-
associated protein that is also known as AKIP1 (A-kinase-interacting protein 
1) (Kitching et al 2003; Sastri et al 2005). Notably, three putative splice 
variants of BCA3/AKIP1 have previously been described, i.e. the full length 
AKIP1a and the alternatively spliced AKIP1b and AKIP1c (Sastri et al 2005) 
(Fig. 4.1). In our yeast two-hybrid assay, parkin pulled down both AKIP1a and 
AKIP1c. For ease of discussion, I shall refer to full length AKIP1a as BCA3 






Figure 4.1 Splice variants of BCA3/AKIP1. Schematic depiction of the various 
splice variants of BCA3/AKIP1. 
 
4.2.3.  Relationship between BCA3 and breast cancer  
 BCA3 was originally described by Kitching and colleagues in 2003 as 
a proline-rich protein of unknown function that is highly expressed in breast 
cancer and prostate cell lines, although its expression is minimal in normal 
breast and prostate tissues (Kitching et al 2003). To extend this finding, I 
recruited the help of Dr. Yu Yingnan from Professor Bay Boon Huat’s 
laboratory (NUS Department of Anatomy) to perform an expression analysis 
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of BCA3 in normal and malignant breast tissue via real-time PCR. Primers 
specific to the full-length 1a isoform, were used for this experiment. 
Consistent with the original report, we detected a significant (albeit modest) 
increase in BCA3 expression (the full-length isoform) in breast cancer tissues 







Figure 4.2 BCA3 expression in normal and cancerous human breast tissues. Bar 
graph showing the expression of BCA3 as determined by qPCR between Normal and 
Breast cancer tissues. 
 
Using the same set of primers, we also looked at BCA3 expression 
across different stages of breast cancer via TissueScan qPCR array. One way 
ANOVA analysis revealed a significant difference of BCA3 expression among 
cases of different stages (Fig. 4.3). These results suggest that BCA3 
expression variation is relevant to breast cancer, although it remains unclear 
whether this breast cancer-related protein is fulfilling a pro- or anti-oncogenic 
role. 
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Figure 4.3 BCA3 expression in normal and cancerous human breast tissues. Bar 
graph showing the expression of BCA3 as determined by qPCR among different 
stages of breast cancer. 
 
4.2.4  Cloning and expression of human BCA3  
To examine the properties of BCA3 in cultured cells, I cloned both full 
length BCA3 and the 1c variant from SH-SY5Y, a human cell line, into a 
mammalian expression vector (Fig. 4.4A). When ectopically expressed in 
HEK293 cells and subsequently fractionated on SDS-PAGE, myc-tagged 
BCA3 (full length and 1c variant) migrate above and below the 25 kD marker 
respectively, according to their expected size of 28 (full length) and 20 kD 
(1c) (Fig. 4.4B). 
 
Figure 4.4 Cloning of BCA3/AKIP1. (A) PCR-mediated amplification of 
BCA3/AKIP1 cDNAs from mRNA prepared from SH-SY5Y cells. Gel pieces 
corresponding to full length BCA3/AKIP1a and 1c were excised and cloned into a 
mammalian expression vector. (B) Anti-myc immunoblot of lysate prepared from 
BCA3/AKIP1-transfected HEK293 cells showing the expression of myc-tagged 
BCA3 and 1c variant, as indicated. Asterisk refers to non-specific bands. 
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4.2.5  BCA3 resides both in the cytoplasm and nucleus  
Although initially described as a nuclear protein, cytoplasmic BCA3 
expression has also been reported in recent studies (Leung & Ngan 2010; Yu 
et al 2007). Consistent with this, immunofluorescence analysis revealed that 
ectopically-expressed BCA3 in HEK293 cells resides in both the nucleus and 
cytoplasm under normal culture conditions (Fig. 4.13A, top panel). Similarly, 
endogenous BCA3 is also found in the nucleus as well as the cytoplasm (Fig. 
4.5A). In agreement with this, anti-BCA immunoblotting of lysates prepared 
from cells expressing exogenous BCA3 showed the presence of BCA3 in both 
nuclear and cytosolic fractions (Fig. 4.5B). 
 
Figure 4.5 Cellular localization of BCA3. (A) Confocal microscopy images 
showing localization of endogenous BCA3 in HEK 293 cells as revealed by anti-
BCA3 immunostaining. (B) Subcellular fractionation of BCA3-expressing HEK293 
cells into nucleus (N), Cytosol (C) and Microsome (M) fractions. The purity of the 
crude nucleus and cytosol fractions is determined by anti-lamin and anti-AKT 
immunostaining. Note that exogenous BCA3 distributes in both nucleus and cytosol 
fractions. 
 
4.2.6  Interaction between parkin and BCA3 in mammalian cells 
Given that a population of BCA3 resides in the cytoplasm where 
parkin is primarily localized, it is possible that the association of the two 
proteins occurs outside the nucleus. To examine the interaction between parkin 
and BCA3 in mammalian cells, FLAG-tagged parkin was co-expressed with 
myc-tagged BCA3 (full length and 1c variant) in HEK293 cells for co-
immunoprecipitation analysis. Supporting our Y2H interaction study, I found 
Characterization of BCA3/AKIP1    98 
that both forms of BCA3 co-immunoprecipitated parkin (Fig. 4.6A). Similar 
observation was made when parkin was co-expressed with an untagged 
version of full length BCA3 (not shown). Interestingly, other than monomeric 
parkin, the commonly observed high molecular weight (HMW) species of 
ectopically expressed parkin also bind robustly to BCA3 immunoprecipitates 
(Fig. 4.6A). Thus, parkin and BCA3 appears to be binding partners in 
mammalian cells. To examine whether the interaction between parkin and 
BCA3 is specific, I repeated the above experiment with either c-Cbl or 
HHARI (related RING-containing E3 members) in place of parkin. No 
appreciable binding between BCA3 and these RING-E3 members was found 
(Fig. 4.6B & C), suggesting that the interaction between parkin and BCA3 is 
specific. 
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Figure 4.6 BCA3 interacts with parkin specifically. Immunoblots showing co-
immunoprecipitation of myc-tagged BCA3 (full length or 1c) with (A) FLAG-tagged 
parkin but not (B) HA-Cbl or (C) HA-HHARI from transfected HEK293 cells. 
 
4.2.7  Parkin N-terminus binds the C-terminal region of BCA3 
To examine whether the interaction between parkin and BCA3 is direct 
or indirect, I performed a binding assay using recombinant full length MBP-
tagged parkin and His-tagged BCA3 and found that the two proteins interacts 
directly in vitro (Fig. 4.7A). To map the region on parkin and BCA3 that is 
responsible for their interaction, I generated a number of N- and C-terminal 
deletion mutants and examined their binding affinity for each other via a GST-
pull down assay. Consistent with the Y2H results above, I found that full 
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length BCA3 binds to GST-parkin (N-term) containing the UBL and linker 
sequence but not to GST-parkin (C-term) containing the RING1-IBR-RING2 
domain (Fig. 4.7B). The interaction between BCA3 and GST-parkin (N-term) 
is retained when BCA3 is deleted of its N-terminus sequence (103-210) but 
abolished when BCA3 is deleted of its C-terminus sequence (1-102) (Fig. 
4.7B), suggesting that the association between parkin and BCA3 is mediated 
by their N- and C-terminus domain respectively. Supporting this, co-
immunoprecipitation analysis revealed that the N-terminus of parkin was 
sufficient to mediate the interaction with BCA3 (Fig. 4.7C). Taken together, 
my results suggest that parkin binds to BCA3 directly and that the interaction 
is mediated by their N- and C-terminus domain respectively. 
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Figure 4.7 Parkin binds BCA3 directly. (A) Immunoblots showing the pull down of 
recombinant MBP-parkin by recombinant His-tagged BCA3. (B) Left, Schematic 
depiction of GST-parkin and BCA3 deletion mutants. Right, Immunoblots showing 
the interaction between GST-parkin and BCA3 deletion mutants. (C) N and C-
terminal parkin mutants were also generated in mammalian vector and expressed in 
cells in the presence or absence of BCA3 expression. Anti-FLAG immunoblots show 
the association of BCA3 with N-term but not C-terminal-containing parkin.  
 
4.2.8 Parkin promotes BCA3 stability  
Given that parkin functions as an E3 ligase, I was curious to know 
whether its presence would affect the steady state level of BCA3.  For this 
purpose, I ectopically expressed BCA3 in HEK 293 cells in the presence or 
absence of exogenous parkin and treated the cells with the protein synthesis 
inhibitor puromycin (100 µM) for various durations to follow the turnover rate 
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of BCA3. Notably, Leung and Ngan have recently reported that BCA3 is an 
unstable protein that has a short half-life (Leung & Ngan 2010). Consistent 
with this, I found that BCA3 was rapidly degraded within the first hour after 
puromycin treatment (Fig. 4.8A & B). Treatment of BCA3-expressing cells 
with the proteasome inhibitor MG132 or the autophagy inhibitor 3-
methylalanine resulted in a marked enhancement of BCA3 expression (Fig. 
4.8C), suggesting that BCA3 was normally degraded by both the proteasome 
and lysosomal systems. Surprisingly, the stability of BCA3 was also 
significantly increased in the presence of parkin co-expression (Fig. 4.8A & 
B). Indeed, BCA3 expression remained detectable after 6 hours of puromycin 
treatment (Fig. 4.8A & B).  
 
 
Figure 4.8 Parkin promotes BCA3 stability. (A) Puromycin pulse chase analysis of 
the turnover rate of BCA3 in the absence or presence of FLAG-parkin. (B) The anti-
BCA3 immunblots from three independent experiments were used to derive the 
relative densitometric units of BCA3, which is presented as a graph. (C) Anti-BCA3 
immunoblots showing the levels of BCA3 in vector transfected cells (-) or BCA3 
transfected cells either left untreated or treated with the proteasome inhibitor MG132 
or the autophagy inhibitor 3-MA, as indicated. 
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4.2.9  Parkin-mediated enhancement of BCA3 stability is specific and 
 independent of its catalytic activity 
To examine if the above phenomenon is specific to parkin, I examined 
the steady state levels of BCA3 in cells co-expressing other E3 ligases. 
Apparently, the observed parkin-mediated stabilization of BCA3 expression 
was a rather selective phenomenon, as several other E3 ligases tested, 
including the closely related HHARI, failed to promote BCA3 stability 
appreciably (Fig. 4.9A).  
 
Figure 4.9 Parkin-mediated stabilization of BCA3 is specific and independent of 
its catalytic activity. (A) Anti-BCA3 immunoblot showing the expression of BCA3 
in cells co-expressing the vector or various E3 ligases, as indicated. (B) Anti-BCA3 
immunoblot showing the expression of BCA3 in cells co-expressing the vector, wild 
type (WT) parkin or an established parkin catalytic mutant (T415N) (C) Top, Anti-
BCA3 immunoblot showing the expression of BCA3 in the absence or presence of 
FLAG-tagged wild type (WT) parkin or parkin 1-137 mutant. Bottom, Anti-FLAG 
(parkin) immunoblot showing the relative expression of parkin in the absence or 
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Next, I sought to determine if the N-terminus domain of parkin, which 
I have shown earlier to bind to BCA3, is sufficient to mediate BCA3 
stabilization. Co-expression studies in HEK 293 cells revealed that not only is 
parkin’s N-terminus region (amino acid 1-237) sufficient to promote BCA3 
stability, the effect appeared significantly stronger than that mediated by the 
full length protein (Fig. 4.9B). However, the linker region needs to be intact as 
a truncated mutant of parkin containing the UBL domain and part of the linker 
region (i.e. from amino acid 1-137) failed to stabilize BCA3 appreciably (Fig. 
4.9C). Similarly, the IBR-R2 mutant of parkin that our lab have previously 
demonstrated to be capable of polyubiquitination also did not enhance the 
stability of BCA3 (Fig. 4.9B), which is consistent with the inability of the 
RING box to bind to BCA3 (Fig. 4.9C). Together, these results suggest that 
parkin-mediated stabilization of BCA3 requires the linker region and is not 
dependent on its catalytic activity. Further supporting this, I found that a 
catalytically null, disease-associated parkin T415N mutant is just as capable as 
the wild type protein in promoting BCA3 stability (Fig. 4.9B).  
 
4.2.10  BCA3 expression does not affect the catalytic activity of parkin 
Given that parkin interactors such as CHIP, Bag5, Nrdp1/FLRF and 
14-3-3η have been shown to regulate its enzymatic function, I was keen to 
know whether BCA3 interaction with parkin would affect its ubiquitin ligase 
activity. However, I found no evidence that BCA3 could alter parkin-mediated 
(auto) ubiquitination (Fig. 4.10). 
 
 













Figure 4.10 BCA3 does not compromise the catalytic activity of parkin. A portion 
of lysates prepared from HEK293 cells transfected with HA-tagged ubiquitin in the 
absence or presence of FLAG tagged and/or BCA3 were subjected to anti-FLAG 
immunoprecipitation followed by anti-HA immunoblotting (left top panel). The blot 
was stripped and reprobed with anti-FLAG to show the amounts of parkin 
immunoprecipitated (left bottom panel). Rights panels show the expression level of 
parkin and HA-ubiquitin (INPUT) 
 
4.2.11  The NEDD8-specific protease SENP8 antagonizes parkin-mediated 
 stabilization of BCA3  
BCA3 was previously reported to be a substrate of NEDD8 (Gao et al 
2006). To examine if neddylation might have a role in parkin-mediated 
stabilization of BCA3, I repeated the above experiments in the presence of an 
increasing dose of SENP8, a NEDD8-specific protease. Overexpression of 
SENP8 accelerated the turnover of BCA3 in a dose-dependent manner 
regardless of the presence or absence of full length or N-terminus parkin co-
expression (Fig. 4.11A), suggesting that neddylation of BCA3 may be 
important for its stability. However, when BCA3 was co-expressed in the 
presence of increasing dose of HA-tagged Nedd8, its degradation was not 
impeded (not shown).  
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Interestingly, SENP8 also promoted a dose-dependent reduction in 
parkin levels (Fig. 4.11A), which raised the possibility that SENP8 could be 
destabilizing BCA3 indirectly through its effect on parkin expression. 
Supporting this, I found that increasing the expression of parkin could 
overcome the antagonistic effect of SENP8 on BCA3 stabilization (Fig. 
4.11B). The effect may be attributable purely to increased parkin dose as 
SENP8 levels were unaffected (Fig. 4.11B). Again, the observed phenomenon 
was not dependent on the catalytic activity of parkin as the expression of a 
parkin mutant devoid of its RING-IBR-RING domain was similarly effective 




































Figure 4.11 SENP8 antagonizes parkin-mediated stabilization of BCA3. (A) 
Immunoblots showing the expression of BCA3 (0.5 µg) in the absence or presence of 
wild-type (WT) parkin or parkin N-terminus domain (aa 1-237) (0.5 µg each) (as 
indicated) and in the absence of presence of increasing concentration of SENP8 (0.25, 
0.5, 1, 2 µg). (B) Immunoblots showing the expression of BCA3 in the absence or 
presence of SENP8 expression and in the absence or presence of increasing 
concentration of wild-type (WT) parkin (0.25, 0.5, 1, 2 µg) or parkin N-terminus 
domain (aa 1-237) (0.25, 0.5, 1 µg). 
 
4.2.12  SENP8 promotes parkin degradation via the autophagy system  
 That a NEDD8-specific protease can affect the steady-state kinetics of 
parkin is clearly of interest. Although a recent report demonstrated that parkin 
can be neddylated, the authors did not mention its relationship to parkin 
turnover (Um et al 2012). To examine whether SENP8-mediated reduction of 
parkin expression is associated with enhanced degradation of the E3 ligase by 
the proteasome, I expressed FLAG-parkin ectopically in HEK293 cells in the 
absence or presence of HA-SENP8 and treated the cells with the proteasome 
inhibitor MG132. Consistent with my results above, parkin levels were 
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reduced in a dose-dependent manner in the presence of SENP8. However, 
compared to untreated cells, MG132 treatment failed to mitigate SENP8-
mediated reduction of parkin expression (Fig. 4.12A). On the other hand, 
when these parkin-SENP8 co-expressing cells were treated with 3-MA - an 
autophagy inhibitor, a dramatic increase in parkin level was recorded (Fig. 
4.12B), suggesting that SENP8 promoted parkin degradation by the lysosomal 
system.  
 
Figure 4.12 SENP8-mediated reduction in parkin level can be rescued by 
autophagy inhibition. (A) Immunoblots showing the expression of parkin in the 
presence or absence of SENP8 in untreated cells or cells treated with 1µM MG132 for 
16 hours. (B) Immunoblots showing the expression of parkin in the presence or 
absence of SENP8 in untreated cells or cells treated with 1µM MG132 or 3-MA for 
16 hours, as indicated 
 
 
4.2.13  Parkin promotes BCA3 localization to the nucleus 
Given that BCA3 can apparently shuttle between the nucleus and 
cytoplasm (Leung & Ngan 2010; Yu et al 2007), we wondered if parkin-
mediated BCA3 stabilization would influence the cellular distribution of 
BCA3. Immunofluorescence analysis of HEK293 cells transfected with BCA3 
with or without parkin revealed that parkin promoted the localization of BCA3 
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in the nucleus (Fig. 4.13A). Within the nucleus, BCA3 tends to be punctate in 
appearance (Fig. 4.13A). This is in agreement with a previous report by Sastri 
and colleagues who demonstrated that nuclear- localized BCA3 is present as 
“speckles” (Sastri et al 2005). Interestingly, whilst parkin co-localized with 
BCA3 in the cytoplasm, BCA3 punctas within the nucleus were generally 
devoid of parkin (Fig. 4.13A), even in some cases when exogenous parkin was 
found in the nucleus (not shown). Similar observation regarding parkin-
induced BCA3 localization to the nucleus was observed in a subcellular 
fractionation study where cell lysates from the nucleus, cytosol and microsome 
fractions were prepared separately from cells expressing BCA3 alone or in the 
presence of parkin (Fig. 4.13B). Indeed, parkin co-expression resulted in a 
dramatic enhancement of BCA3 immunostaining in the nucleus fraction, 
whose purity was ascertained by anti-lamin immunoblotting (Fig. 4.13B). 
Consistent with our observations above, this parkin-mediated effect was 
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Figure 4.13 Parkin promotes BCA3 localization to the nucleus. (A) Confocal 
microscopy images showing the cellular localization of BCA3 (green)  in the absence 
and presence of parkin (red). Inset, graph showing the percentage of BCA3-positive 
cells where the nucleus localization of the protein can be observed (nucleus) or not 
observed (cytosol). (B) Immunoblots showing the subcellular localization of BCA3 in 
the absence or presence of FLAG-parkin and/or HA-SENP8 co-expression. Lamin 
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4.2.14  What is the functional relevance of parkin-mediated enhancement 
of BCA3 stability and nuclear localization? 
Clearly, after demonstrating that BCA3 is a bona-fide interactor of 
parkin and that parkin can promote the stability and nucleus localization of 
this novel partner, it is important to elucidate their functional relationship.  
NFκB activity regulation: A recent study by Gao and colleagues 
demonstrated that BCA3 promotes the nuclear retention and phosphorylation 
of p65, which is part of the p65/p50 NFκB complex, and concomitantly 
enhances NFκB-dependent gene expression (Gao et al 2008). Using a 
luciferase-based NFκB activity assay, they showed that ectopically expressed 
BCA3 increased the transcriptional activity of NFκB induced by phorbol 12-
myristate 13-acetate (PMA). To examine whether parkin-mediated BCA3 
nuclear translocation might promote NFκB-dependent gene expression, I used 
a similar luciferase-based assay to measure NFκB activity under different 
conditions (see Materials and Methods). In the absence of PMA treatment, I 
did not observe any increase in NFκB activity in cells expressing BCA3 and 
parkin either separately or together relative to vector control (Fig. 4.14A). 
Although a clear increase in NFκB activity was seen in cells treated with 
PMA, the enhancement was similar across the board, i.e. the presence or 
absence of parkin co-expression did not significantly affect the activity of 
NFκB in BCA3-expressing cells (Fig. 4.14B). Thus, parkin-mediated BCA3 
nucleus localization does not appear to be relevant to NFκB-dependent gene 
expression. Moreover, my result also differs from that reported by Gao and 
colleagues (Gao et al 2008) in that BCA3 expression in HEK293 cells (same 
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Figure 4.14 BCA3 expression in the absence or presence of parkin co-expression 
fails to augment NFκB activity. (A) Luciferase assay of NFκB-dependent 
transcriptional activity in vector control HEK293 cells or those ectopically 
expressing BCA3 and parkin either alone or in combination. (B) Same as (A) 
except cells were left either untreated (-) or treated with PMA (+). 
 
 Mitochondrial-related processes: Interestingly, another recent report 
demonstrated that p73, a tumor suppressor related to p53, stabilized BCA3 in 
cervical cancer cells (in a manner similar to what I have observed here) and 
promoted the localization of BCA3 to the mitochondria (Leung & Ngan 2010). 
Given the current recognition that parkin is a key regulator of mitochondrial 
autophagy (or mitophagy), I wonder if BCA3 stabilization can exert an effect 
on parkin-mediated mitophagy. To address this, I carried out an established 
mitophagy assay in HeLa cells stably expressing GFP-parkin, which is the 
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most common cell type used for mitophagy-related experiments. Consistent 
with previous reports by our laboratory and others, (Lee et al 2010; Narendra 
et al 2008), treatment of these cells with the mitochondrial uncoupler CCCP 
for 4 hours led to the condensation of depolarized mitochondria (as revealed 
by Tom-20 staining) as well as GFP-parkin at the peri-nuclear region (Fig. 
4.15). At 16 hours post-CCCP treatment, the amount of mitochondria was 
dramatically reduced due to their removal by mitophagy, the process of which 















Figure 4.15 Parkin-mediated mitophagy. Representative images showing the co-
localization and condensation of GFP-parkin and Tom-20 (a mitochondrial marker) 
around the perinucleus region 4 hours after 10 µM CCCP treatment. Tom-20 signal 
begins to disappear at 16 hours post-CCCP treatment and the disappearance of the 
signal is completed at 24 hours post-CCCP treatment. 
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Next, I checked whether overexpression of BCA3 might have an effect 
on parkin-mediated mitophagy. In untreated GFP-parkin expressing HeLa 
cells, ectopic BCA3 expression specifically those residing in the cytoplasm did 
not appear to colocalize much with the mitochondrial marker Tom-20 (Fig. 
4.16A). However, when these cells were treated with CCCP, marked overlap 
of signals between BCA3 and Tom-20 (as well as parkin) was observed (Fig. 
4.16A). Indeed, BCA3 was progressively distributed to the perinucleus region 
where Tom-20/GFP-parkin formed. Importantly, at 24 hours post-CCCP 
treatment, BCA3 expression appeared to compromise parkin-mediated 
mitophagy as a significant population of Tom-20-positive mito-aggresomes 
persisted (Fig. 4.16A), which would otherwise virtually disappear completely 
via parkin-mediated mitophagy (Fig. 4.15). 
Similar observations were obtained when I repeated the above 
experiment with myc-tagged BCA3 (Fig. 4.16B). Together, my results 
suggested that cytosolic BCA3 might repress parkin function in mitochondrial 
quality control, although the precise mechanism underlying BCA3-mediated 



































Figure 4.16 BCA compromises parkin-mediated mitophagy. (A) Representative 
images showing the expression and cellular localization of untagged BCA3 (Morens 
et al), Tom-20 (red0 and GFP-parkin (green) at various time points after CCCP 
treatment following BCA3 transfection in HeLa cells stably expressing GFP-parkin. 
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4.3 Discussion 
 The main finding of the study presented in this chapter is that 
BCA3/AKIP1, a breast cancer-associated protein is a novel interacting partner 
of parkin but unlike its “predecessors”, BCA3, is neither a classical substrate 
nor a clear regulator of parkin. Rather, parkin promotes the stability and 
nuclear localization of BCA3 in a catalytically-independent manner. Further, I 
have demonstrated by means of deletion mutant analysis both in vitro and in 
cultured cells that BCA3 binds to the N-terminus region of parkin, which 
contains the UBL domain and the unique region (a.a. 77-237). This result is 
consistent with my Y2H study which utilized the unique linker domain of 
parkin as bait. Additionally, the stabilization of BCA3 by parkin is mediated 
more effectively by the UBL-linker domain of parkin than by the full length 
protein. The linker region, however, needs to be intact as a truncated mutant of 
parkin which contains the UBL domain and part of the linker region (a.a. 1-
137), failed to elicit a similar effect. Despite my initial effort to identify 
regulators of parkin by making use of this unique linker domain as bait in my 
Y2H screen, BCA3 does not seem to affect the E3 ubiquitin ligase activity of 
parkin as demonstrated in the auto-ubiquitination assay. However, under 
circumstances where BCA3 becomes aggregated, it can apparently inhibit 
parkin function in the clearance of damaged mitochondria via autophagy 
pathway.  
 BCA3 was originally reported in year 2003 as a breast cancer-
associated protein whose expression is elevated in breast cancer and prostate 
cancer cells (Kitching et al 2003). Subsequent studies by others revealed that 
BCA3 normally expresses poorly in breast cells, but is otherwise highly 
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expressed in a number of tissues, including the heart, kidney, lung, liver and 
testis (Sastri et al 2005). The role of BCA3 in tumorigenesis remains to be 
established but two recent studies (Gao et al 2006; Gao et al 2008) have 
identified BCA3 as an interacting partner of p65, a subunit of the NFκB 
heterodimer, thought to be an important player in the pathogenesis of many 
diseases such as cancer, neurodegeneration and autoimmune diseases 
(Baeuerle & Baichwal 1997; Moynagh 2005; Tan et al 2008b).  BCA3 had 
been shown to influence NFκB signaling both positively and negatively 
depending on prevailing cellular conditions and possibly the type of BCA3 
isoforms involved. In one study, the 1b isoform (Fig. 4.1) of BCA3 was found, 
upon neddylation, to bind p65 and repress NFκB-dependent transcription (Gao 
et al 2006) while another study shows that the 1a isoform (Fig. 4.1) promotes 
phosphorylation of p65 by PKA catalytic subunit (PKAc) which leads to 
increased nuclear translocation of p65 and the eventual increase in 
transcription of NFκB and its responsive genes (Gao et al 2008). Interestingly, 
parkin appears to also participate in the NFκB pathway (Henn et al 2007). I 
was therefore interested in examining the functional relevance of BCA3 and 
parkin interaction along the line of NFκB activity regulation. Thus, I 
proceeded with the rationale in mind, that if elevated BCA3 expression (as in 
transient overexpression) leads to upregulation of NFκB pathway, it would 
provide support for its role in tumorigenesis as NFκB is involved in the 
activation of pro-survival pathways important to cancer progression, and 
higher BCA3 expression was reported in breast cancer and prostate cancer 
cells. On the other hand, if elevated BCA3 expression counters the positive 
effect of parkin, and is associated with repressing NFκB activity, the result 
Characterization of BCA3/AKIP1    119 
would then be more relevant to PD pathogenesis than tumorigenesis. 
However, I was unable to witness similar results, be it down- or up-regulation 
of NFκB activity in cells expressing BCA3 and parkin either separately or 
together. Perhaps, it should not be surprising that BCA3 co-expression with 
parkin did not lead to a reduction in NFκB activity since BCA3 is found to not 
down-regulate parkin activity (see Fig. 4.10). Next, despite working with the 
same cell line and the same BCA3 isoform as Gao et al, I failed to observe 
similar upregulation in NFκB activity (Gao et al 2008). A follow-up report by 
Gao and colleagues, seems to provide clues to the lack of similarity in our 
observations. In this study, they found BCA3 expression level to be crucial in 
determining the outcome of PKA-mediated activation of NFκB. Low 
endogenous levels of BCA3 in HEK293 and HeLa cells saw an inhibition of 
NFκB signaling and prevention of PKAc interaction with the p65 subunit of 
NFκB, in the presence of PKA-activating agents. The negative function of 
PKAc on NFκB signaling was reversed by overexpression of BCA3 in these 
cells (Gao et al 2010). However, unlike Gao et al, I observed a rapid turnover 
of ectopically expressed BCA3 protein; as demonstrated by my puromycin-
based pulse chase result (see Fig. 4.8). If indeed, high BCA3 expression level 
is the key to obtaining a significant increase in NFκB signaling, that may 
explain why I was unable to observe such an effect. Although co-expression of 
parkin helps to stabilize BCA3, it is noteworthy that parkin does not promote 
BCA3 stability per se; it in fact, determines the cellular localization of BCA3 
by promoting its nuclear occupancy thereby indirectly prolonging BCA3 
protein half-life. In this respect, parkin may in effect, direct BCA3 away from 
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sites where it can interact and bind to p65, thus accounting for the lack of 
significant change in NFκB signaling. 
 The recently ascribed role of parkin in the clearance of damaged 
mitochondria as elegantly demonstrated by Youle et al, gives additional 
support to the hypothesis that mitochondrial dysfunction is one of the key 
mechanisms underlying PD pathogenesis (Narendra et al 2008). I was curious 
to know if BCA3 stabilization by parkin would exert an effect on parkin-
mediated mitophagy. Interestingly, under normal culture conditions, 
overexpressed BCA3 does not seem to localize much with cellular 
mitochondria. However, upon CCCP treatment, BCA3 gets recruited to the 
perinuclear region where Tom-20 and GFP-parkin are localized to, indicating 
co-localization of BCA3 to depolarized mitochondria. Importantly, despite 
obvious formation of mito-aggresomes, parkin fails to mediate proper 
clearance of these damaged mitochondria at the established time-point of 24h, 
which accordingly, should have witnessed complete clearance. Therefore, 
some form of reciprocal regulation seems to exist between these two 
interacting partners - with parkin stabilizing BCA3 and the latter regulating 
parkin function when it becomes aggregated. Importantly, failure to clear 
damaged mitochondria might trigger a vicious cycle where increase in ROS 
production further impairs mitochondrial function.  
 This has direct implication for both neurodegeneration and 
carcinogenesis. As mentioned earlier in the introduction chapter, the brain, in 
particular the substantia nigra is a pro-oxidative environment due to the 
metabolism of dopamine. Expectedly, increase in ROS can only be detrimental 
to the survival of dopaminergic neurons. Notably, mitochondria are not only 
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the primary source of ROS, they are also victims to the damaging effects of 
free radicals. Mitochondrial DNA (mtDNA) in particular, is exceptionally 
susceptible to the ravages of ROS due to its close proximity to the electron 
transport chain and its lack of protective histones. Besides the brain, the 
hypoxic environment of rapidly proliferating tumor cells also facilitates ROS 
production. Thus, mitochondrial genomic instability leading to respiratory 
dysfunction as a result of oxidative damage induced by ROS could be one of 
the major factors that favors a shift in ATP production to glycolysis, termed 
the Warburg effect, in tumor cells. Related to my study, one can only imagine 
how breast cancer cells that are devoid of or low in parkin expression (see 
Chapter 3) may provide that final push in the transformation process via 
defects in mitochondrial respiration, aided by an elevated BCA3 expression. 
 In accordance with my previous chapter, where I have provided 
evidence in support of parkin as a tumor suppressor, the results presented 
herein, seem to also suggest that the relationship between BCA3, a breast-
cancer associated protein, and parkin to be an opposing one. Although 
tempting, a few questions immediately come to mind. Why would parkin 
function to promote the stability of a protein that is elevated in breast cancer 
cells and which impinges on its function in mitophagy? Perhaps under normal 
physiological condition, the re-localization and stabilization of BCA3 by 
parkin is imperative in the proper regulation of BCA3 function. It is therefore 
interesting to examine the localization of BCA3 in breast cancer cells that are 
devoid of parkin. In addition, proteins of the neddylation machinery seem to 
be involved in the regulation of BCA3 by parkin. Interestingly, neddylation 
has been shown to promote parkin catalytic activity and in my study, SENP8, 
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a NEDD8-specific protease seems to promote parkin degradation via the 
lysosomal system. An intricate balance seems to exist in the regulation of 
parkin via neddylation. Although still in its inchoate stage, protein 
modification via the ubiquitin-like molecule, NEDD8, is likely to be a hotly 
researched topic in the future. The relationship between parkin and BCA3 
might not be as straightforward and though it has been a formidable challenge, 
unraveling the mystery behind the functional relevance for their interaction 








GENERAL DISCUSSION AND CONCLUSIONS 
 
 As mentioned in the introductory chapter, parkin is a frequent target 
for mutations and deletions not only in PD but also in several cancer types. 
Interestingly, while germline mutations of parkin are responsible for 
neurodegeneration associated with PD, somatic parkin mutations are linked to 
different types of cancer which include breast cancer, ovarian cancer, lung 
cancer, colon cancer and glioblastoma. The primary objective of my thesis is 
to characterize this intriguing role of parkin in cancer and more specifically, in 
mammary carcinogenesis. My initial motivation at the start of my candidature 
was to identify novel regulators of parkin in an attempt to better understand 
how this molecule is regulated in vivo and how dysregulation may impinge on 
its function in the brain. Unexpectedly, I isolated a breast cancer related 
protein, BCA3/AKIP1, as a novel parkin interactor during my yeast two-
hybrid screen using a human brain-derived cDNA expression library. This 
finding coupled with the interesting relationship between PD and cancer 
prompted me to take a closer look at parkin’s possible contribution in breast 
carcinogenesis. In the first part of my thesis, I examined the role of parkin in 
breast cancer and found that its expression is dramatically down-regulated 
both at the transcript level as well as the protein level in a variety of breast 
cancer cell lines as well as in primary breast cancer tissues. Importantly, I 
showed that restoration of parkin expression in a parkin-deficient breast cell 
line, MCF7, resulted in significantly reduced proliferation rate and migration 
capacity. Collectively, results obtained in part 1 of my thesis provide strong 
General Discussion and Conclusions   124 
support for the role of parkin as a TSG. The second part of my thesis described 
the isolation and characterization of a novel parkin interactor, BCA3/AKIP1, 
which is a breast cancer-associated gene. An examination of the reciprocal 
effects parkin and BCA3 has on each other, as a result of their interaction, 
showed that the ubiquitn E3 ligase can promote BCA3 protein stability in a 
catalytically independent manner. Of note, however, this change in BCA3 
protein half-life is most likely due to its increased nuclear occupancy 
promoted by parkin, although it remains unclear how nuclear residency of 
BCA3 protects it from proteasomal degradation. Although the mechanism and 
physiological function behind the nuclear promotion of BCA3 by parkin 
remains to be determined, under circumstances where BCA3 forms 
aggregates, mimicking perhaps a pathophysiological setting such as during 
excessive ROS production, aggregated BCA3/AKIP1 could apparently inhibit 
parkin-mediated clearance of damaged mitochondria via autophagy pathway. 
Taken together, the findings presented here suggest possible overlappings in 
the functional roles of parkin in PD pathogenesis and tumorigenesis. Further, 
my results also implicate parkin-BCA3 interaction as a potential link between 
the two seemingly divergent processes. In this concluding chapter, I shall 
discuss these results in perspective. 
 
 
5.1 Parkin at the crossroad of tumors and tremors 
 At first glance, PD and cancer seem to occupy two opposing ends of a 
disease paradigm - one that involves uncontrollable cell death and another that 
is characterized by enhanced survival and incessant growth rate. However, 
upon closer inspection, these two unrelated diseases actually share many 
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similarities in terms of molecular and biochemical pathways. Although the 
contributing pathophysiological factors might overlap, the cellular outcome 
associated with the dysfunction might be entirely different depending on the 
cell types, in particular, terminally differentiated vs mitotically active cells.  
 Cell cycle dysregulation - It is becoming increasingly apparent that 
aberrant cell cycle activation is one of the common mechanisms underlying 
both neuronal apoptosis and cancer progression. Many studies have shown the 
re-expression of cell-cycle related proteins, such as cyclins or cyclin-
dependent kinases (CDKs) in neurons that are undergoing apoptotic cell death 
(Copani et al 2001; Dragunow et al 1997; Padmanabhan et al 1999). This is 
certainly unexpected of neurons that are supposed to remain in perpetual cell 
cycle arrest, committed to their differentiated state. Additionally, a variety of 
stimuli have been demonstrated to trigger aberrant cell cycle re-entry in post-
mitotic neurons, and these include excitoxicity, ischemia, and withdrawal of 
growth factors amongst others (Dragunow et al 1997). Clinical evidence in 
support of unscheduled cell cycle activation and neuronal apoptosis was 
demonstrated by fluorescence in situ hybridization study where DNA 
replication was detected at certain chromosomal loci in hippocampal neurons 
afflicted by Alzheimer’s disease (Yang et al 2001). To a huge extent, cell 
cycle transitions in proliferating cells are regulated post-translationally by the 
tightly controlled proteolysis of cyclins and CDKs by the UPS. It is therefore 
possible to envisage that aberrant function of UPS components, such as parkin, 
could result in unchecked cell cycle progression and the activation of 
apoptosis in post-mitotic differentiated neurons. At the opposing end of the 
spectrum, accumulation of cyclins and CDKs in proliferating breast epithelial 
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cells, as a result of dysfunctional UPS would most likely result in 
uncontrollable growth rate. Notably, cyclin E a substrate of parkin, is often 
found to be elevated in parkin-deficient PD brains (Staropoli et al 2003), in 
addition to being abnormally expressed in ~40% of breast cancers (Buckley et 
al 1993; Keyomarsi & Pardee 1993). This demonstrates that both breast 
epithelial cells and neurons are equally dependent on the UPS function in the 
maintenance of their cellular state. On the other hand, my study has uncovered 
CDK6 as another potential link between PD pathogenesis and cancer. In 
dividing cells, CDKs expression is important for cellular regulation of 
proliferation, differentiation, senescence and apoptosis. In contrast, the 
expression of CDKs (except CDK5) is repressed in post-mitotic neurons 
(Nguyen et al 2002). Misregulation of CDKs is therefore another possible 
mechanism underlying neurodegeneration, although it is unclear currently how 
CDK6 expression might be affected in neurons lacking functional parkin. 
Future experiments should clarify the potential role (if any) of CDK6 in PD 
pathogenesis. 
 Mitochondrial dysfunction - Cellular homeostasis is highly dependent 
on mitochondria for the aerobic production of ATP. Neuronal cells, in 
particular, are highly reliant on these “cellular power plants” for their survival 
as they depend solely on oxidative phosphorylation for ATP production. 
Conceivably, injuries sustained by mitochondria in neurons have to be handled 
efficiently and rapidly to ensure cellular survival, and this process is often 
mediated by the activation of mitophagy. Cancer cells, on the other hand, are 
primarily dependent on glycolytic pathway for ATP generation since tumor 
mitochondria often have compromised bioenergectic capacity. It is believed 
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that the alteration in energy metabolism exhibited by tumor cells is one of the 
contributing factors in the transformation process. Similar to neurons, the 
induction of mitophagy in the setting of cancer would also aid in the survival 
of the organism as a whole. It is imaginable therefore, that any form of 
disruption to parkin-mediated autophagy clearance of damaged mitochondria 
could contribute either to premature neuronal cell death or neoplastic 
transformation, depending on cellular context. In this respect, the interaction 
of parkin with BCA3 seems to be of particular relevance to PD and 
tumorigenesis. Protein misfolding and aggregation as highlighted previously, 
are common occurrences seen in both PD and cancer. This observation is most 
likely due to an increase in free radical production both in the pro-oxidant 
brain and the hypoxic tumor. Treatment of HeLa cells with the mitochondria 
uncoupler, CCCP leads to artificial induction of mitochondrial depolarization, 
loss of outer mitochondrial membrane (OMM) stability and leakage of free 
radicals which mimic to a certain extent, the highly oxidative states often 
experienced by dopaminergic neurons and cancer cells. Thus, CCCP treatment 
provides a window into possible outcomes of BCA3 on parkin function in the 
event of mitochondrial dysfunction. The suppression of parkin-mediated 
mitophagy by BCA3 as a result of increased oxidative stress indicates an 
interrelation of two common risk factors i.e. mitochondrial dysfunction and 
impaired mitophagy. Importantly, this relationship between BCA3 and parkin 
provides us with a common thread that unites the historically separate fields of 
cancer and neurodegeneration.  
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5.2 BCA3: villian or hero in tumorigenesis? 
 BCA3, originally described as a breast cancer-associated protein, was 
found to be elevated in breast cancer-derived cell lines as well as in primary 
breast tissues. The immediate assumption that follows naturally is that BCA3 
likely possesses oncogenic properties. However, keeping in mind the changes 
that accompany cells during their neoplastic transformation process, one 
would be careful when considering whether an observed increase in the 
expression of a protein is a cause or consequence of tumorigenesis. That being 
said, attempts made to elucidate the function of BCA3 have provided 
important insights into some roles played by the protein, including 
transcriptional regulation through NFκB signaling (Gao et al 2006; Gao et al 
2008), actin cytoskeleton remodeling (Yu et al 2007) and regulation of γ-
irradiation induced apoptotic reponse (Leung & Ngan 2010). Although these 
data have been insightful, they did not help clarify the dichotomous role BCA3 
plays in cancer as exemplied by its regulation of NFκB signaling (one group 
showed a positive influence while another demonstrated a negative effect) and 
its role in sensitizing cervical cancer cells to the apoptotic effects of γ-
irradiation. To add another level of complexity, BCA3 exists as three isoforms 
(Fig. 4.1) whose interaction and influence on one another is an area that has 
not been looked at. These splice variants which lack certain functional 
domains present in the full-length protein, could very well serve to modulate 
the activity of BCA3, thus accounting for the varied observations regarding 
BCA3’s role in tumorigenesis. Additionally, very little is known about how 
BCA3 may be modified post-translationally, except that it can be neddylated 
(Gao et al 2006) and possibly ubiquitinated. Preliminary results from my work 
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seem to suggest a role for parkin in the promotion of BCA3 neddylation as 
demonstrated indirectly via the inclusion of SENP8, a NEDD8-specific 
protease (Fig. 4.11A). In addition, neddylated BCA3 appears to be the 
stabilized form as increasing dose of SENP8 leads to an increased reduction of 
BCA3 protein levels, although SENP8 co-expression apparently also leads to 
parkin downregulation. Interestingly, even though parkin appears to regulate 
re-localization of cytosolic BCA3 to the nucleus, BCA3 seems to only co-
localize with parkin in the cytosol. Once in the nucleus, nuclear staining of 
BCA3 does not overlap with that of parkin. Perhaps upon nuclear entry, BCA3 
would dissociate from parkin to participate in the regulation of gene 
expression for proper cellular function. It would therefore be of great interest 
to identify genes which are targets of BCA3 in order to further elucidate the 
functional relevance of parkin and BCA3 interaction. This would in turn 
provide us with more insights into the role of BCA3 in tumorigenesis.  
 
5.3  Linking the brain and the breast 
 Studies have shown that estrogen, a sex steroid, is a powerful 
neuroprotectant, (Cyr et al 2000; Kipp et al 2006; Peri & Serio 2008) capable 
of functioning as a radical scavenger (Behl 2002), an anti-apoptotic signal 
(Ivanova et al 2002; Lee et al 2003) and an attenuator of  pro-inflammatory 
processes (Kipp et al 2007; Vegeto et al 2008) in the brain, among many 
others. More importantly, recent findings have also implicated estrogen in the 
maintenance of mitochondrial integrity (Araujo et al 2008; Arnold et al 2008; 
Simpkins & Dykens 2008) and regulation of mitochondrial respiratory chain 
biogenesis (Chen et al 2009). As mentioned in the introductory chapter, 
General Discussion and Conclusions   130 
neuropathological processes are often closely related to malfunctions in 
mitochondria as demonstrated by drugs which specifically target components 
of mitochondrial respiratory chain such as MPTP and rotenone (Dick et al 
2007; Frigerio et al 2006). Estrogen has been found to promote the expression 
of mitochondrial proteins and enhance mitochondrial transcription (Van Itallie 
& Dannies 1988). Perhaps neuronal cells are capable of inducing an 
upregulation in the levels of estrogen under stressful conditions. While 
estrogen may seem as a very attractive therapeutic strategy for PD, studies 
have also shown that estrogen and its metabolites are carcinogenic to breast 
epithelial cells and cumulative exposure to estrogen promotes breast cancer 
risk (Colditz 1998; Russo et al 2003; Russo et al 2001; Spink et al 2009). 
Estrogen therefore may pose as a double-edged sword, protecting neurons on 
one hand and promoting breast cancer proliferation on the other. Interestingly, 
parkin has been implicated recently in the modulation of estrogen-related 
receptors (ERRα, β and γ) expression levels by promoting their ubiquitination 
and degradation (Ren et al 2011). Notably, parkin-mediated degradation of 
these receptors serves mainly to regulate the expression of monoamine 
oxidases, MAOs A and B which are responsible for ROS production due to 
dopamine oxidation (Ren et al 2011). Besides regulating expression of MAOs, 
these orphan receptors, in particular ERRα has been shown to stimulate the 
production of aromatase which converts steroidal precursors to active forms 
that are used for estrogen synthesis (Horard & Vanacker 2003). These findings 
therefore suggest that parkin dysfunction would lead to an increase in MAOs 
expression as well as estrogen production and provide strong support for the 
dual role of parkin in preventing breast carcinogenesis and PD pathogenesis. 
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Indeed, the breast and brain might not be such disparate entities based on their 
co-dependence on functional parkin. 
 
5.4 Conclusions 
 The original purpose of my research project was to examine how 
modulation of parkin activity by its interactor could result in PD pathogenesis. 
To this end, I have found a novel interactor of parkin that does not influence 
parkin activity under normal conditions but instead whose stability and 
cellular localization are modulated by parkin in a catalytically-independent 
manner. The identification of this novel parkin interactor, BCA3/AKIP1, 
which turned out to be a breast-cancer associated protein also prompted me to 
examine the potential role of parkin in tumorigenesis, specifically in breast 
cancer development. At the end of my research project, I have provided results 
that strongly support a role for parkin as a TSG in breast carcinogenesis. 
Taken together, my results suggest that compromised parkin function is not 
only relevant to the development of PD but also likely represents a risk factor 
in breast cancer development. Thus, two seemingly unrelated diseases could 
share a common denominator despite having entirely different disease 
phenotypes. 
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